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INTRODUCTION
1.1 Overview of Gastro esophagal reflux disease (GERD):
Gastroesophageal reflux disease (GERD), gastro-oesophageal reflux disease
(GORD), gastric reflux disease, or acid reflux disease is chronic symptoms or
mucosal damage caused by stomach acid coming up from the stomach into the
esophagus.
Gastro esophagal reflux disease (GERD) is a more serious form of gastro
esophageal reflux (GER), which is common. Gastro esophageal reflux (GER) occurs
when the lower esophageal sphincter (LES) opens spontaneously, for varying
periods of time or does not close properly and stomach contents rise up into the
esophagus. Gastro esophageal reflux (GER) is also called acid reflux or acid
regurgitation, because digestive juices called acids rise up with the food. The
esophagus is the tube that carries food from the mouth to the stomach. The lower
esophageal sphincter (LES) is a ring of muscle at the bottom of the esophagus that
acts like a valve between the esophagus and stomach.
Gastro esophagal reflux disease (GERD) is usually caused by changes in the
barrier between the stomach and the esophagus, including abnormal relaxation of
the lower esophageal sphincter, which normally holds the top of the stomach closed
impaired expulsion of gastric reflux from the esophagus, or a hiatal hernia. These
changes may be permanent or temporary ("transient"). [1]
When acid reflux occurs, food or fluid can be tasted in the back of the mouth.
When refluxed stomach acid touches the lining of the esophagus it may cause a
burning sensation in the chest or throat called heartburn or acid indigestion.
Occasional GER is common and does not necessarily mean one has GERD.
Persistent reflux that occurs more than twice a week is considered GERD and it can
eventually lead to more serious health problems. People of all ages can have
GERD. [2]
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1. Causes, incidence, and risk factors: [2]
Reflux may cause symptoms, or it can even damage the esophagus.
The risk factors for reflux include:
1. Alcohol (Possibly)
2. Hiatal hernia (a condition in which part of the stomach moves above the
diaphragm, which is the muscle that separates the chest and abdominal cavities).
3. Obesity: Some studies have shown that GERD is highly prevalent in patients
who are morbidly obese and that a high body mass index (BMI) is a risk factor
for the development of this condition[3]
4. Pregnancy
5. Scleroderma
6. Smoking
Heartburn and gastroesophageal reflux can be brought on or made worse by
pregnancy and many different medications. Such drugs include:
1. Anticholinergics (e.g., for seasickness)
2. Beta-blockers for high blood pressure or heart disease
3. Bronchodilators for asthma
4. Calcium channel blockers for high blood pressure
5. Dopamine-active drugs for Parkinson's disease
6. Progestin for abnormal menstrual bleeding or birth control
7. Sedatives for insomnia or anxiety
8. Tricyclic antidepressants.
Symptoms:
More common symptoms are:
1. Feeling that food is stuck behind the breastbone
2. Heartburn or a burning pain in the chest (under the breastbone)
3. Nausea after eating
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Less common symptoms are:
4. Bringing food back up (regurgitation)
5. Cough or wheezing
6. Difficulty swallowing
7. Hiccups
8. Hoarseness or change in voice
9. Sore throat
1.1.1 Pathophysiology of GERD: [3]
Schematically, the esophagus, lower esophageal sphincter (LES), and
stomach can be envisioned as a simple plumbing circuit as described by Stein and
coworkers. The esophagus functions as an antegrade pump, the LES as a valve, and
the stomach as a reservoir. The abnormalities that contribute to GERD can stem
from any component of the system.
1. Poor esophageal motility decreases clearance of acidic material.
2. A dysfunctional LES allows reflux of large amounts of gastric juice.
3. Delayed gastric emptying can increase volume and pressure in the reservoir
until the valve mechanism is defeated, leading to GERD.
4. From a medical or surgical standpoint, it is extremely important to identify
which of these components is defective so that effective therapy can be
applied.
Esophagal defence mechanism:
Esophageal defense mechanisms can be broken down into 2 categories
(i.e.,esophageal clearance and mucosal resistance). Proper esophageal clearance is
an extremely important factor in preventing mucosal injury. Esophageal clearance
must be able to neutralize the acid refluxed through the lower esophageal sphincter.
(Mechanical clearance is achieved with esophageal peristalsis; chemical clearance
is achieved with saliva). Normal clearance limits the amount of time the
esophagus is exposed to refluxed acid or bile and gastric acid mixtures. Abnormal
peristalsis can cause inefficient and delayed acid clearance.
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Dysfunction of the lower esophagal spincter:
The lower esophageal sphincter (LES) is defined by manometry as a zone of
elevated intraluminal pressure at the esophagogastric junction. For proper LES
function, this junction must be located in the abdomen so that the diaphragmatic
crura can assist the action of the LES, thus functioning as an extrinsic sphincter. In
addition, the LES must have a normal length and pressure and a normal number of
episodes of transient relaxation (relaxation in the absence of swallowing).
LES dysfunction occurs via one of several mechanisms: transient relaxation
of the LES (most common mechanism), permanent LES relaxation, and transient
increase of intra-abdominal pressure that overcomes the LES pressure.
Delayed gastric emptying:
The postulated mechanism by which delayed gastric emptying may cause
GERD is an increase in gastric contents resulting in increased intragastric pressure
and, ultimately, increased pressure against the lower esophageal sphincter. This
pressure eventually defeats the LES and leads to reflux. However, objective studies
have produced conflicting data regarding the role of delayed gastric emptying in the
pathogenesis of GERD.
Hence the physiologic and anatomic factors that prevent the reflux of gastric juice
from the stomach into the esophagus include the following:
1. The lower esophageal sphincter (LES) must have a normal length and pressure
and a normal number of episodes of transient relaxation (relaxation in the
absence of swallowing).
2. The gastro esophageal junction must be located in the abdomen so that the
diaphragmatic crura can assist the action of the LES, thus functioning as an
extrinsic sphincter. The presence of a hiatal hernia disrupts this synergistic action
and can promote reflux.
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3. Esophageal clearance must be able to neutralize the acid refluxed through the
LES. (Mechanical clearance is achieved with esophageal peristalsis. Chemical
clearance is achieved with saliva.)
4. The stomach must empty properly.
Esophagitis:[3]
Esophagitis (esophageal mucosal damage) is the most common complication
of GERD, occurring in approximately 50% of patients.
A rapid urease test (RUT) is performed on the esophageal biopsy sample.
The result is positive for esophagitis.
Esophagitis may be diagnosed using endoscopy, although it cannot always
be appreciated on endoscopy. As many as 50% of symptomatic patients with
GERD demonstrate no evidence of esophagitis on endoscopy. Still, documentation
of this complication is important in diagnosing GERD. Degrees of esophagitis are
described by the Savary-Miller classification as follows.
 Grade I – Erythema,
 Grade II – Linear nonconfluent erosions,
 Grade III – Circular confluent erosions,
 Grade IV – Stricture or Barrett esophagus.
Stricture: Strictures are advanced forms of esophagitis and are caused by
circumferential fibrosis due to chronic deep injury. Strictures can result in dysphagia
and a short esophagus. Gastroesophageal reflux strictures typically occur in the mid-
to-distal esophagus and can be visualized on upper GI tract studies and endoscopy.
Presence of a stricture with a history of reflux can also help diagnose GERD.
Barret esophagus: The most serious complication of long-standing or severe
GERD is the development of Barrett esophagus. Barrett esophagus is present in 8-
15% of patients with GERD and may progress to adenocarcinoma. Barrett esophagus
is thought to be caused by the chronic reflux of gastric juice into the esophagus. It is
defined by metaplastic conversion of the normal distal squamous esophageal
epithelium to columnar epithelium.As with esophageal stricture; the presence of
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Barrett esophagus indicates the need for surgical consultation and treatment (usually
surgical fundoplication).
Treatment for GERD:4,5,6
The goals of treatment are:
 To bring the symptoms under control so that the individual feels better;
 Heal the esophagus of inflammation or injury;
 Manage or prevent complications such as Barrett's esophagus or stricture;
 And maintain the symptoms of GERD in remission so that daily life is
unaffected or minimally affected by reflux.[4]
Lifestyle modification: 3, 4, 5,6,7,8
It involves avoidance of factors that may bring on symptoms or make them
worse, such as dietary changes or changes in daily routine. While diet does not
cause GERD, reflux and its most frequent complaint of heartburn can be aggravated
by foods. Certain medications can aggravate symptoms.
 Position: Gravity plays an important role in controlling reflux. The people who
have a less than perfect lower esophageal sphincter (LES) find that if they lie
down after a large meal, food comes back into the esophagus and heartburn
occurs. Maintaining an upright posture until the meal is digested may prevent the
heartburn. If heartburn occurs regularly at night, consider raising the head of the
bed or inserting a triangular wedge to keep your esophagus above the stomach.
Avoid exertion after a meal. It contracts the abdominal muscles and forces food
through a weakened sphincter. This is especially true of tasks that require
bending such as lifting or cleaning the floor.
 Food: A large meal will empty slowly from the stomach and exert pressure on
the LES. It is best to eat early in the evening so that the meal is digested at
bedtime. All meals should be eaten in relaxed stress-free surroundings. Smaller
meals and an upright, relaxed posture should help minimize reflux.
 Certain foods compromise the sphincter's ability to prevent reflux, and are best
avoided before lying down or exertion. These differ from person to person. Many
person find that fats, onions, and chocolate as particularly troublesome. Alcohol
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often provokes heartburn, by compromising the LES, irritating the esophagus,
and by stimulating stomach acid production. Common beverages such as coffee
(both caffeinated and decaffeinated), tea, cola, tomato juice, and citrus juice may
aggravate symptoms by irritating the esophagus or stimulating stomach acid
production. [7].
 Being overweight can promote reflux. Excess abdominal fat puts pressure on the
stomach and the loss of even a moderate amount of weight makes many people
feel better. Pregnancy is often troubled by heartburn, particularly in the first three
months.
Prescription Medication:
Prescription medications to treat GERD and ulcers include drugs called
H2 receptor antagonists (H2-blockers) and proton pump inhibitors which help to
reduce the stomach acid which tends to exacerbate symptoms, and work to
promote healing, as well as promotility agents which aid in the clearance of acid
from the esophagus.
 H2 receptor antagonists:
The H2 receptor antagonists are reversible competitive blockers of
histamine at the H2 receptors, particularly those in the gastric parietal cells,
where they inhibit acid secretion. They are highly selective, do not affect the H1
receptors, and are not anticholinergic agents.[3]
Since the mid-1970’s H2-receptor antagonists have been used to treat GERD
and ulcer disease. In GERD, H2-receptor antagonists improve the symptoms of
heartburn and regurgitation and heal mild-to-moderate esophagitis. Symptoms are
eliminated in somewhat over 50% of patients with twice a day prescription dosage
of the H2-receptor antagonists. Healing of esophagitis may require higher dosing.
These agents maintain remission in about 25% of patients. H2-receptor antagonists
are generally less expensive than proton pump inhibitors and provide adequate,
cost-effective approaches as the first-line treatment as well as maintenance agents
in GERD and ulcer disease.8
The [H2]-receptor antagonists differ in their potency. This difference has no
apparent clinical importance in peptic ulcer disease but may be a factor in their
efficacy in GERD. Thus, higher doses of a less potent agent such as Cimetidine are
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needed to demonstrate healing of erosive esophagitis. The more potent [H2]-
antagonists, Ranitidine, Nizatidine and Famotidine, are more likely to be effective
at standard duodenal ulcer doses. Ranitidine has been approved by the FDA at a
dosage of 150 mg four times daily for healing erosive esophagitis and at 150 mg
twice daily for relief of GERD symptoms. Nizatidine, the newest of the [H2]-
receptor antagonists, was the first to be approved by the Food and Drug
Administration for both symptom relief and healing of esophagitis at standard
duodenal ulcer doses (150 mg twice per day). Recently Famotidine has also
received approval for symptom relief and healing of erosive esophagitis at standard
duodenal ulcer dosage (20 mg twice daily), and at a higher dosage (40 mg twice
daily) for severe esophagitis.
A newly developed H2 receptor antagonist Lafutidine is also used in the
treatment of GERD and Peptic ulcer.9 A recent crossover study in healthy
volunteers did show that a single dose (10 mg) of this novel H2-RA is able to
increase intragastric pH more quickly than a single dose (20 mg) of Rabeprazole,
the fastest amongst the available PPIs.[10]
GER is a chronic illness often requiring long-term therapy. Because of their
established safety records, the H2-receptor antagonists are the agents best suited for
continuous long-term therapy. Reduction of H2-receptor antagonists to half doses at
bedtime, in a fashion analogous to that used in maintenance therapy for duodenal
ulcer is seldom successful for GERD. Most GERD patients require at least full split
dose therapy when H2-antagonists are used for chronic continuous treatment. In
summary, H2-blockers are effective in relieving heartburn and somewhat effective
in heating esophagitis. Because of their excellent safety profile, they are still the
primary prescription pharmacologic agents used in the treatment of GERD.
 Proton pump inhibitors:
Proton pump inhibitors (PPIs), such as omeprazole, and more recently
lansoprazole, have been found to heal erosive esophagitis (serious forms of GERD)
more rapidly than H2 receptor antagonists. PPIs provide not only symptom relief,
but also symptom resolution in most cases, even in those with esophageal ulcers.
Studies have shown PPI therapy can provide complete endoscopic mucosal healing
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of esophagitis at 6 to 8 weeks in 75% to 100% of cases. Daily PPI treatment
provides the best long-term maintenance of esophagitis, particularly in keeping
symptoms and disease in remission for those patients with moderate-to-severe
esophagitis, plus this form of treatment has been shown to retain remission for up to
five years. 8
Although effective and safe, currently available PPIs are still far from the
ideal antisecretory compound. Currently available PPIs have notable limitations.11
 Prokinetic agents:
Prokinetic agents, such as Metoclopramide (Reglan) , Bethanecol, and
newer ones like Cisapride and Domperidone  improve the motility of the esophagus
and stomach and increase the lower esophageal sphincter (LES) pressure to help
reduce reflux of gastric contents. They also accelerate gastric emptying.
Metoclopramide is a dopamine receptor antagonist that has been evaluated in
the treatment of GERD in several trials. The few well-designed studies demonstrate
an improvement in symptom control over placebo using metoclopramide 10 mg po
q.i.d.[13] Metoclopramide is less effective, however, in both symptom control and
healing of esophagitis when compared with H2RA therapy.[12]
Domperidone (MotiliumR) is a dopamine antagonist available from outside the
United States or from sites within the U.S. via the Internet or Food and Drug
Administration (FDA) referral. Unlike metoclopramide, domperidone does not
cross the blood–brain barrier and thus has a better safety profile, with no significant
CNS side effects and only a minor incidence of gynecomastia and galactorrhea. [12]
 Antacids: Antacids are a class of medications that act by directly neutralizing
gastric acid. Calcium carbonate (TumsR) is still a commonly used antacid, as
is magnesium hydroxide (MylantaR, MaaloxR), and magnesium hydroxide with
or without calcium (RolaidsR). Powdered sodium bicarbonate is also available,
but is less frequently used. Antacids provide rapid, but temporary, relief of
heartburn (lasting 30 to 60 minutes) and thus may require frequent dosing.
 Alginic acid, a polysaccharide derived from seaweed, may be used in
combination with antacids (GavisconR) for the treatment of GERD. This agent
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creates a viscous layer atop the gastric juice and may impede acid reflux by
physically preventing acid from entering the esophagus while delivering
coadministered antacids to the esophagus. Antacid/alginic acid combinations
have been demonstrated to be superior to placebo for the relief of GERD
symptoms and this therapy may also be used for the treatment of mild and
infrequent heartburn.
Summary:
GERD is a common problem with a wide spectrum of clinical severity. A
variety of tests are available to evaluate patients with GERD, and physicians must
be aware of the type of information that each test can provide. Conservative
measures employing nonpharmacologic therapy are appropriate for all patients.
Initial pharmacologic therapy usually involves an H2-receptor antagonist or
antacids. In many patients, long-term continuous therapy with an H2-receptor
antagonist given in split doses is needed. Omeprazole is indicated for short-term
therapy of severe erosive esophagitis and symptoms refractory to H2-receptor
antagonists.
1.2 Oral drug delivery - A Overview
Since decades, illnesses are being treated clinically through delivery of
drugs to the patients in the form of some pharmaceutical dosage forms like tablets,
capsules, pills, creams, liquids, ointments, aerosols, injectable and suppositories.
To achieve and maintain the concentration of an administered drug within
therapeutically effective range, it is often necessary to take drug dosage several
times in a day and these results in a fluctuating drug plasma levels. [15]
Oral drug delivery is the most desirable and preferred method of
administering therapeutic agents for their systemic effects. In addition, the oral
medication is generally considered as the first avenue investigated in the discovery
and development of new drug entities and pharmaceutical formulations, mainly
because of patient acceptance, convenience in administration, and cost-effective
manufacturing process.[18]
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The oral route of administration has wide acceptance and constitute
50-60 % of total drug formulations. This trend is still continuing since oral route is
the most preferred route due to its several advantages including ease of ingestion,
self-medication and most importantly, patient compliance.[2] In conventional oral
drug delivery systems, there is little control over the release of drug from
formulations. The effective concentration of drug at the target site can be achieved
by intermittent administration of grossly excessive doses. This in most situations
often results in constantly changing, unpredictable and often sub-therapeutic
plasma concentrations leading to marked side-effects. [16]
Oral drug delivery is the most convenient route of administration
among all the routes that have been explored for systemic delivery of drugs using
different dosage forms. The oral absorption of drugs is often limited due to short
gastric residence time (GRT) i.e., the time required for the content of the stomach
to enter small intestine. This retention time is almost similar for particular species.
In case of human beings it is 3 to 4 hours. Due to short transit time many of the
conventional dosage forms are unable to deliver the active agents completely in the
stomach. However, recent research findings showed that the use of gastro-retentive-
dosage forms could avoid these associated problems.
Oral drug delivery is the most convenient route of administration
among all the routes that have been explored for systemic delivery of drugs using
different dosage forms. The oral absorption of drugs is often limited due to short
gastric residence time (GRT) i.e., the time required for the content of the stomach
to enter small intestine. This retention time is almost similar for particular species.
In case of human beings it is 3 to 4 hours. Due to short transit time many of the
conventional dosage forms are unable to deliver the active agents completely in the
stomach. However, recent research findings showed that the use of gastro-retentive-
dosage forms could avoid these associated problems. [18]
The development of pharmaceutical products for oral delivery,
irrespective of its physical form, involves varying extent of optimization of dosage
form characteristics within the inherent constraints of gastro intestinal (GI)
physiology. Therefore the fundamental understanding of various disciplines,
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including gastro intestinal (GI) physiology, pharmacokinetic, pharmacodynamic
and formulation design are essential to achieve a systematic approach to the
successful development of an oral pharmaceutical dosage form. The more
sophisticated a delivery system, the greater are the complexities in design and
optimization of the system. In any case, the scientific framework required for the
successful development of an oral drug delivery system consists of a basic
understanding of the following three aspects:
1. Physicochemical, pharmacokinetic and pharmacodynamic characteristics of the
drug
2. The anatomical and the physiological characteristics of the GIT
3. Physicochemical characteristics and drug delivery mode of the dosage form to be
designed. 19
PROBLEMS AND BARRIERS TO ORAL DRUG DELIVERY: 18
The biggest problem in oral drug delivery is low and erratic bioavailability,
which mainly results from one or more factors such as poor aqueous solubility,
slow dissolution rate, low intestinal permeability, and instability in GI milieu, high
first-pass metabolism through liver and/or intestine variable GI transit, and P-gp
(Pico gram) mediated efflux. This, in turn, may lead to unreproducible clinical
response or a therapeutic failure in some cases due to subtherapeutic plasma drug
levels. Indeed, the incomplete and variable oral bioavailability will have its most
serious impact for drugs with a narrow ‘‘therapeutic window’’ (e.g., theophylline,
carbamazepine, quinidine, etc.) From an economic point of view, low oral
bioavailability results in the wasting of a large portion of an oral dose, and adds to
the cost of drug therapy, especially when the drug is an expensive one. It is,
therefore, extremely important that these issues be considered and a suitable
technique (or an animal model) be used while estimating the contributions from
each factor responsible for low and/or variable bioavailability.18
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Physicochemical Barriers:
1) Aqueous solubility:
It has long been recognized that before an orally administered drug becomes
available for absorption at specific sites within the GI tract, it must be dissolved in
the GI fluid. Since both the dissolution rate and the maximum amount of a drug that
can be dissolved are dictated by the solubility of the drug in the medium aqueous
solubility of a drug could be regarded as a key factor responsible for low oral
bioavailability of poorly water-soluble drugs, thereby limiting their therapeutic
potential.
2) Lipophilicity:
The lipid solubility or lipophilicity of drugs has long been recognized as a
prerequisite for transcellular diffusion across the intestinal membrane. Traditionally,
the lipophilicity of drug substances is expressed as the apparent partition coefficient
or distribution coefficient (log P) between n-octanol and an aqueous buffer (pH 7.4),
which is pH-dependent in the case of ionisable compounds. In general, compounds
with low log P are poorly absorbed, whereas compounds with log P > 1 offer
satisfactory absorption. It is important, however, that the drug possess an optimum
lipophilicity, as too low or too high lipophilicity may result in less than optimum
oral bioavailability.
3) Aqueous boundary layer:
The aqueous boundary layer or the unstirred water layer (UWL) is a more or
less stagnant layer, about 30–100 mm in thickness, composed of water, mucus, and
glycocalyx adjacent to the intestinal wall that is created by incomplete mixing of the
lumenal contents near the intestinal mucosal surface.33 The glycocalyx is made up of
sulfated mucopolysaccharides, whereas mucus is composed of glycoproteins
(mucin), enzymes, and electrolytes. Until recently, the resistance of the UWL to
intestinal absorption was believed to be correlated to the effective intestinal
permeability (Peff) values of the solutes; however, considerable evidence suggests
instead that the available surface of the apical membrane of the intestinal mucosa is
the main barrier for both actively and passively absorbedsolutes. It is also interesting
to note that coadministration of food and prokinetic (motility inducing) agents such
as cisapride tends to decrease the thickness of UWL by increasing segmental and
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propagative contractions respectively, which may have implications for drug
dissolution in the GI tract. The reverse is true for some viscous soluble dietary fibers,
such as pectin, guar gum and sodium carboxymethylcellulose, which may increase
the thickness of UWL by reducing intraluminal mixing and could possibly decrease
the intestinalexsorption of lipophilic drugs like quinidine and thiopental.
Biological Barriers:
1) Intestinal epithelial barrier:
The intestinal epithelial layer that lines the GI tract represents the major
physical barrier to oral drug absorption.
2) Gastrointestinal transit:
From the oral delivery standpoint, both gastric emptying time (GET) and
small intestinal transit time (SITT) are considered important since the majority of
drugs are preferentially absorbed in the upper parts of the GI tract (stomach,
duodenum, and jejunum). Moreover, the stomach and intestines have a limited
site for drug absorption. This is known as an ‘‘absorption window.’’ The
relatively short GET (1–3 hours) and SITT (3–5 hours) thus provide limited time
for drug absorption through the major absorption zone. These problems are
further aggravated by the highly variable nature of the gastric emptying process,
which can vary depending on several physiological factors, such as food, age,
posture, exercise, body mass index, circadian rhythm, etc.; pathological factors,
such as stress, diabetes, Crohn’s disease, and motility disorders; and
pharmaceutical factors, such as size and density of formulation and
coadministration of drugs like anticholinergic and prokinetic agents.
3) Food effect:
The coadministration of drugs with food is known to result in decreased,
delayed, increased, or accelerated drug absorption, which may have pharmacokinetic
and pharmacodynamic implications.
Metabolic and biochemical barriers:
1) Presystemic Metabolism:
Drugs administered orally are subject to presystemic metabolism via luminal
metabolism, first pass intestinal metabolism, first pass hepatic metabolism.
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P-Glycoprotein(p-Gp) and other efflux systems:
P-Gp can significantly contribute to the barrier function of the intestinal mucosa.
1.3 CURRENT TECHNOLOGIES IN ORAL DRUG DELIVERY: [18]
Over the last 3 decades, many novel oral drug therapeutic systems have been
invented along with the appreciable development of drug delivery technology.
Although these advanced Drug delivery system (DDS) are manufactured or
fabricated in traditional pharmaceutical formulations, such as tablets, capsules,
sachets, suspensions, emulsions, and solutions, they are superior to the conventional
oral dosage forms in terms of their therapeutic efficacies, toxicities, and stabilities.
Based on the desired therapeutic objectives, oral DDS may be assorted into
three categories: immediate-release preparations, controlled-release preparations,
and targeted-release preparations. [18]
1. Immediate release preparations:[20]
The term “immediate release” pharmaceutical formulation includes any
formulation in which the rate of release of drug from the formulation and/or the
absorption of drug, is neither appreciably, nor intentionally, retarded by galenic
manipulations.
DESIRED CRITERIA FOR IMMEDIATE RELEASE DRUG DELIVERY
SYSTEM
Immediate release dosage form should-
In the case of solid dosage it should dissolve or disintegrate in the stomach within a
short period.
1. In the case of liquid dosage form it should be compatible with taste masking.
2. Be portable without fragility concern.
3. Have a pleasing mouth feel.
4. It should not leave minimal or no residue in the mouth after oral administration.
5. Exhibit low sensivity to environmental condition as humidity and temperature.
6. Be manufactured using conventional processing and packaging equipment at low
cost.
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7. Rapid dissolution and absorption of drug, which may produce rapid onset of
action.
POTENTIAL CANDIDATE FOR IMMEDIATE RELEASE ORAL DOSAGE
FORM ARE:
Analgesics and anti inflammatory agent, Anthelmentics, Antibacterials,
Antiarhythmic, Anti malarial, Anti protozoal , Anti ulcer, Anti thyroid agents, Anti
migraine agents etc
Advantages of Immediate Release Drug Delivery System
An immediate release pharmaceutical preparation offers:
1. Improved compliance/added convenience.
2. Improved stability.
3. Suitable for controlled/sustained release actives.
4. Allows high drug loading.
5. Ability to provide advantages of liquid medication in the form of solid
preparation.
6. Adaptable and amenable to existing processing and packaging machinery.
7. Cost- effective.
Excipients used in immediate release preparations: 14
Excipients balance the properties of the actives in immediate release dosage
forms. This demands a thorough understanding of the chemistry of these excipients to
prevent interaction with the actives. These inactive food-grade ingredients, when
incorporated in the formulation, impart the desired organoleptic properties and product
efficacy. Excipients are general and can be used for a broad range of actives, except
some actives that require masking agents.
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Bulking material:
Bulking materials are significant in the formulation of fast-dissolving tablets.
The material gastro intestinal contributes functions of a diluent, filler and cost
reducer.
Lubricants:
Lubricants, though not essential excipients, can further assist in making these
tablets more palatable after they disintegrate in the mouth. Lubricants remove
grittiness and assist in the drug transport mechanism from the mouth down into the
stomach level.
Flavours and sweetener:
Flavours and taste-masking agents make the products more palatable and
pleasing for patients. The addition of these ingredients assists in overcoming
bitterness and undesirable tastes of some active ingredients.
Super disintegrants:
A disintegrant is an excipient, which is added to a tablet or capsule blend to
aid in the break up of the compacted mass when it is put into a fluid
environment.
 Advantages:
1. Effective in lower concentrations
2. Less effect on compressibility and flowability
3. More effective intragranularly
 Some super disintegrants are:
1) Sodium Starch Glycolate (Explotab, primogel) used in concentration of 2-8 %
& optimum is 4%. Mechanism of Action: Rapid and extensive swelling with
minimal gelling.
2) Cross-linked Povidone (crospovidone) (Kollidone) used in concentration of 2-
5% of weight of tablet. Completely insoluble in water.
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Mechanism of Action: Water wicking, swelling and possibly some deformation
recovery. Rapidly disperses and swells in water, but does not gel even after
prolonged exposure. Greatest rate of swelling compared to other disintegrants.
3) Low-substituted hydroxyl propyl cellulose, which is insoluble in water. Rapidly
swells in water. Grades LH-11 and LH-21 exhibit the greatest degree of swelling.
Certain grades can also provide some binding properties while retaining
disintegration Capacity. Recommended concentration 1-5% .
4) Cross linked carboxy methyl cellulose sodium (i.e. Ac-Di-sol) Croscarmellose
sodium: Mechanism of Action: Wicking due to fibrous structure, swelling with
minimal gelling. Effective Concentrations: 1-3% Direct Compression, 2-4% Wet
Granulation.
Gas producing disintegrants:
Gas producing disintegrants are used especially where extra rapid disintegration
or readily soluble formulation is required. Composition is based upon the same
principles as those used for effervescent tablets, the most common being mixtures
of citric & tartaric acids plus carbonates or bicarbonates.
In many instances lower concentration can be used with gas producing
disintegrants than are required by other disintegrating agents. Certain peroxides that
release oxygen has been tried, but they do not perform as well as those releasing
carbon dioxide.
Conventional Technique Used In the Preparation of Immediate Release Tablets
* Tablet molding technique
* Direct compression technique
* Wet granulation technique
* Mass extrusion technique
 Tablet Moulding:
In this technology, water-soluble ingredients are used so that tablet
disintegrate and dissolve rapidly. The powder blend is moistened with a hydro
alcoholic solvent and is moulded in to tablet using compression pressure lower than
used in conventional tablets compression. The solvent is then removed by air-drying.
Moulded tablets have a porous structure that enhances dissolution.
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 Direct Compression Method:
In this method, tablets are compressed directly from the mixture of the drug
and excipients without any preliminary treatment. The mixture to be compressed
must have adequate flow properties and cohere under pressure thus making pre-
treatment as wet granulation unnecessary.
 Wet Granulation Method:
Wet granulation is a process of using a liquid binder to lightly agglomerate
the powder mixture. The amount of liquid has to be properly controlled, as over-
wetting will cause the granules to be too hard and under-wetting will cause them to
be too soft and friable. Aqueous solutions have the advantage of being safer to deal
with than solvent-based systems but may not be suitable for drugs which are
degraded by hydrolysis.
 Mass-Extrusion:
This technology involves softening the active blend using the solvent mixture
of water-soluble polyethylene glycol and methanol and subsequent expulsion of
softened mass through the extruder or syringe to get a cylinder of the product into
even segments using heated blade to form tablets.
Evaluation of immediate release tablets:
Evaluation of Blend:
The prepared blend is evaluated by following tests.
 Angle of repose
 Bulk density
 Tapped density
 Carr’s index
 Hauser’s ratio
Evaluation of Tablets:
The tablets are subjected to the following quality control tests:
 Weight variation
 Friability
 Hardness
 Disintegration
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 In vitro Dissolution
 Stability studies
2. Controlled release Preparations:41
Over the past decades, the treatment of illness has been accomplished by
administering drugs to the human body via various pharmaceutical dosage forms,
like tablets. These traditional pharmaceutical products are still commonly seen today
in the prescription and
over-the-counter drug market place. To achieve and maintain the drug
concentration in the body within the therapeutic range required for a medication,
it is often necessary to take this type of drug delivery system several times a day.
This yields an undesirable ‘‘seesaw’’ drug level in the body.
Figure.No.1
A number of advancements have been made recently in the development of
new techniques for drug delivery. These techniques are capable of regulating the rate
of drug delivery, sustaining the duration of therapeutic action, and/or targeting the
delivery of drug to a specific tissue. These advancements have already led to the
development of several novel drug delivery systems that could provide one or more
of the following benefits:
1. Controlled administration of a therapeutic dose at a desirable rate of delivery.
2. Maintenance of drug concentration within an optimal therapeutic range for
prolonged duration of treatment.
3. Maximization of efficacy-dose relationship.
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4. Reduction of adverse side effects.
5. Minimization of the needs for frequent dose intake.
6. Enhancement of patient compliance.
CLSIFICATION OF CONTROLLED RELEASE DRUG DELIVER SYSTEM:
Based on the technical sophistication of the controlled-release drug delivery systems
(CrDDSs) that have been marketed so far, or that are under active development,
the CrDDSs can be classified as follows:
1. Rate-pre-programmed drug delivery systems.
2. Activation-modulated drug delivery systems.
3. Feedback-regulated drug delivery systems.
4. Site-targeting drug delivery systems.
In this article, the scientific concepts and technical principles behind the
development of this new generation of drug-delivery systems are outlined and
discussed.
RATE-PREPROGRAMMED DRUG DELIVERY SYSTEMS:
In this group of CrDDSs, the release of drug molecules from the delivery
systems has been pre-programmed at a specific rate profile. This is accomplished by
system design, which controls the molecular diffusion of drug molecules in and/or
across the barrier medium within or surrounding the delivery system. Fick’s laws of
diffusion are often followed. These CrDDSs can further be classified as follows:
1. Polymer membrane permeation-controlled drug delivery systems.
2. Polymer matrix diffusion-controlled drug delivery systems.
3. Polymer (membrane/matrix) hybrid-type drug delivery systems.
4. Micro reservoir partition-controlled drug delivery systems.
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Polymer Membrane Permeation-Controlled Drug Delivery Systems:
In this type of CrDDS, a drug formulation is either totally or partially
encapsulated in a drug reservoir compartment whose drug-releasing surface is
covered by a rate-controlling polymeric membrane. The drug reservoir can be drug
solid particles, a dispersion of drug solid particles, or a concentrated drug solution in
a liquid- or solid-type dispersing medium
Polymer Matrix Diffusion-Controlled Drug Delivery Systems:24
The drug release from these system is time dependent and is given by,
dQ/dt = (ACrDp/2t) ½……………………………………….. (1.1)
Where,
dQ/dt is rate of drug release
A is loading dose
Cr is the drug solubility in polymer
t is time and
Dp is the drug diffusivity in Polymer.
Mode of release from hydrophilic matrix dosage form:
Hydrophilic matrix dosage forms essentially consist of a compressed blend of
hydrophilic polymer and drug. According to the generally accepted mechanism, the
drug release from hydrophilic matrix dosage forms starts when the tablet comes in
contact with gastrointestinal fluid. The surface of the tablet hydrates to release
exposed drug and at the same time form a viscous polymer mucilage or gel. This gel
fills the interstices within the tablet, retarding further ingress of liquid.
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The concentration of polymer within the hydrated layer ranges from dilution
at the outer surface to around 90 % at the boundary of drug core. Within this layer,
drug in various states of dissolution (un-dissolved in dilute solution; in saturated
solution) is distributed amongst the other ingredients of the tablets.
Drug release occurs immediately from the surface (burst-effect) followed by
diffusion and/or erosion of the hydrated layer. The relative proportions of drug
released by diffusion and erosion are determined by the drug’s solubility properties
and by the physical and chemical nature of the hydrated polymer. This in turn is
influenced by other factors, including drug characteristics, dissolution medium and
others which have to be investigated.
Matrix type tablets:
Matrix tablets are one of the most widely used oral sustained-release systems
containing a therapeutic agent, homogeneously dissolved or dispersed, in a
compressed water-swellable, soluble or erodible core. The mechanism of drug
release from polymeric matrices involves solvent penetration, hydration, swelling of
the polymer, diffusion of the dissolved drug in the matrix and erosion of the gel
layer. Initially the diffusion coefficient of the drug in the dehydrated hydrogel is very
low, but increases significantly as the gel imbibes water. Interactions between water,
polymer and drug are the primary factors for Sustained-release. Various formulation
variables such as polymer grade, drug/polymer ratio, drug solubility and polymer
particle size can influence drug release rate to a greater or lesser degree.
One of the most important stages in the formulation process is the selection
of the polymeric matrix formers, due to the fact that the design of these systems have
been focused on the concept of the polymeric hydration to protect the tablet from
rapid disintegration and dissolution to delay the drug release rate.
One of the least complicated approaches to the manufacture of sustained-
release dosage forms involves the direct compression of blends of drug, retardant
material and additives to form a tablet in which drug is embedded. Alternately,
retardant drug blends may be granulated prior to compression.  The first class
consists of retardants that form insoluble; the second class represents water-insoluble
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materials that are potentially erodible; and the third class consists of polymers that
form hydrophilic matrices. Loading doses are best included as the second layer of a
two-layer tablet or in a coating applied to the matrix core.
Characteristics to be considered in the design of matrix system: 24
1. The chemical nature of support (generally polymeric nets).
2. The physical state of the drug (dispersed in molecular or particulate form or
both).
3. The matrix shape and alteration in volume as a function of time.
4. The route of administration (oral administration remains the most widely used
but other routes are adaptable).
5. The release kinetics model.
Classification of Matrix Systems:
The classification of matrix systems can be based on several criteria namely-
matrix structure, release kinetics (must be zero-order), controlled-release properties
(diffusion, erosion and/or swelling) and chemical nature and properties of the
applied materials. The various types of matrices are –
1. Mineral Matrix
 Drug retained in the support
 Drug adsorbed on the support
2. Hydrophilic Matrix
 Unlimited swelling, delivery by diffusion
 Limited swelling, controlled delivery through swelling
3. Inert Matrix
 Controlled delivery by diffusion
4. Lipidic Matrix
 Delivery by diffusion
 Delivery by surface erosion
5. Biodegradable Matrix
 Non-lipidic
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Materials Used for Hydrophilic Matrix System
The polymers used for preparing hydrophilic matrix tablets are categorized into
three groups -
1. Cellulose derivatives
Hydroxyethyl cellulose, hypromellose (HPMC) and sodium carboxymethyl
cellulose.
2. Non-cellulosic natural or semisynthetic polymers
Agar-agar, guar gum, xanthan gum, alginates, polysaccharides of mannose and
galactose, chitosan and modified starches.
3. Polymers of acrylic acid
Carbomers 934, 971P, 974P, 71G
HPMC Matrix Systems. 42, 43, 44, 45
One of its most important characteristics is high swelling ability, which has a
significant effect on the release kinetics of an incorporated drug. Diffusion, swelling,
and erosion are the most important rate-controlling mechanism of commercially
available controlled-release products.
The physiochemical properties of HPMC is strongly affected by –
i) The methoxy group
ii) The hydroxypropoxy group content and
iii) The molecular weight
Mechanism of drug release from HPMC matrices 46, 47
1. At the beginning of the process, steep water concentration gradients are formed
at the polymer-water interface resulting in water imbibition into the matrix.
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2. Due to the imbibition of water, HPMC swells, resulting in dramatic changes of
polymer and drug concentrations, and increasing dimensions of the system.
3. Upon contact with water the drug dissolves and diffuses out of the device.
4. With increasing water content the diffusion co-efficient of the drug increases
substantially
5. In case of poor water-solubility, dissolved and non-dissolved drug coexist within
the polymer matrix.
6. In case of high initial drug loadings, inner structure of the matrix changes
significantly during drug release, becoming more porous and less restrictive for
diffusion upon the depletion.
Advantages of hydrophilic matrix systems 49
1. With proper control of manufacturing process, reproducible release profiles are
possible.
2. There is an immediate-release of a small amount of active principle but there is
no risk of dumping of large part of the dose.
3. Large capacity to incorporate drugs which allows them to release large doses.
4. The preparation processes are very simple. Matrix tablet can be made by direct
compression or through conventional dry or wet granulation methods.
5. A class of inexpensive substances with official organizations acceptance.
Polymer (Membrane/Matrix) Hybrid-Type Drug Delivery Systems:
This type of CrDDS is developed with the objective of combining the
constant drug release kinetics of polymer membrane permeation-controlled drug
delivery systems with the mechanical superiority of polymer matrix diffusion-
controlled drug delivery systems.
Microreservoir Partition-Controlled Drug Delivery Systems:
In this type of CrDDS, the drug reservoir is a suspension of drug solid
particles in an aqueous solution of a water-miscible polymer, like polyethylene
glycols. This forms a homogeneous dispersion of many discrete, unleachable,
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microscopic drug reservoirs in a biocompatible polymer, like silicone elastomers.
The microdispersion is achieved by applying a high-energy dispersion technique.
Different shapes and sizes of drug-delivery devices can be fabricated from this
microreservoir-type CrDDS by molding or extrusion techniques.
ACTIVATION-MODULATED DRUG DELIVERY SYSTEMS:
In this group of CrDDSs, the release of drug molecules from the delivery
systems is activated by some physical, chemical, or biochemical processes and/or
facilitated by energy supplied externally .The rate of drug release is then controlled
by regulating the process applied or energy input. Based on the nature of the process
applied or the type of energy used, these activation-modulated CrDDSs can be
classified into the following categories:
1. Physical means:
a. Osmotic pressure-activated drug delivery systems.
b. Hydrodynamic pressure-activated drug delivery systems.
c. Vapor pressure-activated drug delivery systems.
d. Mechanical force-activated drug delivery systems.
e. Magnetics-activated drug delivery systems.
f. Sonophoresis-activated drug delivery systems.
g. Iontophoresis-activated drug delivery systems.
h. Hydration-activated drug delivery systems.
2. Chemical means:
a. pH-activated drug delivery systems.
b. pH-activated drug delivery systems.
c. Ion-activated drug delivery systems.
d. Hydrolysis-activated drug delivery systems.
3. Biochemical means:
a. Enzyme-activated drug delivery systems.
b. Biochemical-activated drug delivery systems.
Chapter 1 Introduction
Dept of pharmaceutics 28 J.K.K.Nattraja college of Pharmacy
FEEDBACK-REGULATED DRUG DELIVERY SYSTEMS:
In this group of CrDDSs, the release of drug molecules is activated by a
triggering agent, such as a biochemical substance, in the body via some feedback
mechanisms. The rate of drug release is regulated by the concentration of a
triggering agent detected by a sensor built into the CrDDS.
SITE-TARGETING DRUG DELIVERY SYSTEMS:
Ideally, the path of drug transport should also be under control. Then, the
ultimate goal of optimal treatment with maximal safety can be achieved. This can be
reasonably accomplished by the development of a CrDDS with a site-targeting
specificity.
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CAPSULE – AS DOSAGE FORM:
Capsules are unit doses of drugs enclosed within soluble shells of gelatin or
similar material, intended to swallow as a whole. Hard capsules were invented in
1833 in America. They were (and are today) made of gelatin and consist of two
parts, a body and a cap (they were supplied ready made but were filled in the
pharmacy). Capsules are available in many different sizes and shapes and can be
used for administration of powders, semisolids and liquids. A capsule is a smooth,
slippery, easy to swallow and tasteless shell of any convenient shape containing
drugs. Capsules are made principally of gelatin blends and may contain small
amounts of certified dyes, opacifing agents, plasticizers and preservatives.
Advantages of Capsule dosage form:
1. It is tasteless and particularly useful for drugs having unpleasant odour or taste.
2. It is economically produced in large quantities and has many pleasing colors.
3. It provides ready availability of the contained drug.
4. Manufacturing is easier as it uses minimal excipients and only little pressure is
5. Required while compacting as compared to tabletting.
Hard gelatin capsules consist of two parts: the base or body, the longer and
lesser diameter portion and the cap, which is the shorter and slightly larger diameter
portion. The cap is designed to slide over the base portion and form a snug seal. For
human use, eight different sizes of gelatin capsules are generally used, ranging from
the smallest.No.5 through the largest, No.000. The numerical designation for a
capsule is arbitrary and bears no indication as to the capacity of the capsule. The
capacity of a capsule is dependent upon the density and characteristics of the
powders in the application. The capsule size only offers a relative volume
designation.
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Table.No.1. Empty hard gelatine capsule different size.
Size Outer diameter(mm)
Height or locked
length (mm)
Actual
volume(ml)
000 9.97 26.14 1.37
00 8.53 23.30 0.95
0 7.65 21.7 0.68
1 6.91 19.4 0.50
2 6.35 18 0.37
3 5.82 15.9 0.30
4 5.31 14.3 0.21
5 4.91 11.1 0.13
Disadvantages:
Capsules are not suitable for drugs that are very soluble, such as salts
(potassium chloride, potassium bromide, ammonium chloride).In these situations,
the fluid penetrating the capsule rapidly dissolves the salt and creates a highly
concentrated solution, which can cause nausea and vomiting when it contacts with
the gastric mucosa. Strongly efflorescent or deliquescent materials are not suitable
for capsules since efflorescent materials may cause capsules to soften, when water is
lost. Strongly deliquescent powders may make the capsule shell brittle, when the
moisture is extracted from the shell into the powder.
Chapter 2 Literature Review
Dept of pharmaceutics 31 J.K.K.Nattraja college of pharmacy
LITERATURE REVIEW
The oral drug delivery system has expanded over a past decade. With the
development of new drug entities, the treatment of disease has become more
organised with reduction in deaths due to various reasons like inappropriate
dosage regimens, over dosing etc. The treatment nowadays has become more
focussed with new dosage forms coming in and new combinations being given.
The present drug delivery system is developed for treatment of Gastro
esophagal reflux disease and non ulcer dyspepsia.
The drug delivery system consists of administering the H2 receptor
antagonist i.e. Lafutidine and the prokinetic agent Domperidone together in such
a way that the Lafutidine is given as immediate release form and Domperidone is
provided in timed release form such that around 40% of the total dose of
Domperidone is released as immediate release form and the remaining dose is
released over a period of 24 hours. 0Many challenges were faced during the
development of this drug delivery system. To overcome these challenges, prior
art was reviewed and the final drug delivery system was designe.
Literature Review
1. Jain et al 50 US patent number US 2007/0160664 A1 describes a
pharmaceutical composition comprising a Proton Pump inhibitor and
Domperidone. In this invention Domperidone is provided in immediate release
and a delayed release form. The solubility of delayed release form is increased
in the intestine (pH 6.8) by incorporation an organic acid.
2. Badwan et al 51 US Patent number 5,646,131 describes methods for
solubilising drugs using Cyclodextrins and Carboxylic acids. The invention
describes improving the solubility of drugs which are insoluble in water
preferably basic drugs by using organic carboxylic acids like Citric acid,
Tartaric acid etc.
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3. Broad et al 52 US patent number 5,705,190 describes methods for solubilising
Basic drugs using organic carboxylic acids containing C3-C20 carbon atoms.
The preferred organic acids are Mallic acid, succinic acid, glutaric acid,
glutamic acid and citric acid. Citric acid is the acid of choice in the present
invention.
4. Khan et al 53 Prepared sustained release tablets of Domperidone using
Hydroxy propyl methyl cellulose K100 LV. The drug release in this case was
controlled by hydration of polymer used, which form gelatinous barrier layer at
the surface of the matrix.
5. Nagarsenkar et al 53describe coevaporates of Domperidone prepared using
polymers by solvent evaporation technique. The drug release rate was
dependent on concentration of polymer in the coevaporates. Dissolution of
drug in phosphate buffer pH 6.8 increased as concentration of hydroxyl propyl
methyl cellulose phthalate (HPMC-p) in coevaporates was increased.
6. Wan et al 55, 56 studied the action of hydroxypropylmethycellulose (HPMC) on
aqueous penetration into matrices containing HPMC of varying viscosity and
concentration. They reported that incorporation of HPMC into matrices
improved wetting and enhanced water uptake into the matrices. As the
molecular weight and concentration of HPMC increase the water uptake by
system was greater. They concluded that the action of HPMC on aqueous
uptake was depended on the molecular weight of HPMC.
7. Sung et al 57, 58 compared different viscosity grades of HPMC (Methocel®
K100LV, K15, K100). The fastest release of drug was achieved for the
K100LV formulation. The K4M formulation exhibited a slightly greater drug
release than K15M and K100M. Due to the lack of a significant difference in
the release profiles between K15M and K100M, the authors suggested a
limiting HPMC viscosity of 15000cP, above which if viscosity increased, the
release rate would no longer  decrease. Similarly, formulations containing
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higher HPMC viscosity grades had slower HPMC release, but no limiting
HPMC viscosity was observed for polymer release.
8. Aronchick et al, 59 US patent number US 2010/0255096 A1 describes the
composition and methods for transmucosal delivery of domperidone.
9. Kajino et al 60,61 described the use of  pyrrole compounds including Lafutidine
for the treatment of diseases like gastroesophagal reflux disease (GERD) ,
peptic ulcer,  NSAIDs incduced gastric acid secretion etc.The invention also
describes superiority of these compounds for the treatemnet of above
mentioned diseases as compared to currently available propton pump inhibitors
(PPIs).
10. Satyam et al US patent number US2011/0263526 A1 described the use of
Nitric oxide releasing drugs including lafutidine for the treatment of GERD
and other gastric disorders.
11. Hill et al 62US patent number US 2010/0216754 described the use of  H2
receptor blockers including Lafutidine for the treatment of Gastroesophagal
reflux disease (GERD) as well as for non Gastroesophagal reflux disease
(NERD).
12. Plachetka et al, 63 US patent number US 2006/0165797 describes the use of
alkaline buffering agents to deliver the drugs H2 blocker Lafutidine to the
acidic environment of stomach.It also describes the use of enteric coating
composition to deliver the acid labile drugs to the intestine.
13. Hiroshi sato et al 65, 66 studied the effect of Lafutidine on gastric mucosa.
Based on the study carried out by them it was concluded that Lafutidine is a
novel, potent antisecretory agent having lost lasting antisecretory effect. Their
findings say that:
Lafutidine is a novel histamine H2-receptor antagonist with both antigastric
secretory and gastroprotective actions. In experimental animal models, it has
been shown to have several unique characteristics; among them a potent
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protective effect against indomethacin induced intestinal ulceration and
necrotizing agent–induced gastroduodenal damage. The effect of the drug has
been shown to be mediated at least partially by capsaicin-sensitive sensory
neurons, independent of its antisecretory activity; the mucoprotective effect of
Lafutidine was shown to be antagonized by hCGRP8-37 or attenuated by
chemical deafferentation with a high dose of capsaicin. No data in the literature
indicate that Lafutidine increases CGRP release from the afferent sensory
neurons and increases the plasma concentration of CGRP.
14. Carmelo Scarpignato 64,67 (Laboratory of Clinical Pharmacology, Department
of Anatomy, Pharmacology & Forensic Sciences, School of Medicine &
Dentistry, and University of Parma, Italy) found that Lafutidine among other
newly developed drugs is the most promising drug which can be used for the
treatment of GERD and non ulcer dyspepsia.
They found that; conversely from Ranitidine and Famotidine, Lafutidine
increases both daytime and night time intragastric pH in H. pylori-negative
subjects and conversely from omeprazole (and other PPIs) its efficacy is not
influenced by the CYP2C19 genotype status. Study in healthy volunteers did
show that a single dose (10 mg) of Lafutidine is able to increase intragastric
pH more quickly than a single dose (20 mg) of Rabeprazole, the fastest
amongst the available PPIs. Both in fasting conditions and in the postprandial
state, the duration of the antisecretory action was longer than that of the PPI
because the drug maintained the pH over a given threshold for a sustained
period of time.
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AIM AND OBJECTIVE
The aim of the present study is to formulate a novel drug delivery based
fixed dose combination therapy for the treatment of Gastroesophageal Reflux
disease (GERD) and non ulcer dyspepsia (NUD).
The drug delivery system is a combination of a H2 receptor blocker and a
Prokinetic agent. Usually the H2 blockers are administered once a day while
prokinetic agents are prescribed thrice daily. The present formulation has been
utilised to tackle the differences in dosing frequency of these two drugs. The
formulation not only ensures patient convenience but also gives high relief rate.
The H2 blocker given is Lafutidine, which is a newly developed drug,
classified as 2nd generation H2 blocker. The prokinetic agent is Domperidone which
relieves the dysmotility associated with GERD as well as NUD.
Lafutidine is provided in immediate release form which has antisecretory
action, protects the gastric mucosa and thus helps in raising the intragastric pH. Both
these actions of Lafutidine are longer as compared to PPI’s as Lafutidine can
maintain the intragastric pH over an extended period of time. [21]
Domperidone acts as a gastrointestinal emptying (delayed) adjunct and
peristaltic stimulant. Domperidone facilitates gastric emptying and decreases small
bowel transit time by increasing esophageal and gastric peristalsis and by lowering
esophageal sphincter pressure.
Hence to summarize in brief, the various objectives that would be obtained from the
current formulation are:
 To reduce the dosage frequency.
 To formulate a capsule this ensures patient convenience and also gives high
relief rate.
 To provide cost–effective product.
 To formulate a combination therapy of a prokinetic agent and a gastric acid
lowering compound which is more effective than mono therapy.
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PLAN OF WORK
The present research work was planned as follows
1. Literature survey
2. Procurement of Drug and suitable excipient
3. Selection of suitable excipients based on Literature search
4. Preformulation study
 Active Pharmaceutical ingredient characterization:
i) Particle size analysis (Malvern Particle size measurement, sieve analysis.)
ii) Flow properties (Bulk density, Tapped Density, Haunsner Ratio,
Compressibility Index)
iii) Solubility and standard curve
 Compatibility study
 DSC Observation
5. Formulation
 Wet Granulation
6. Evaluation
a) Precompression Parameters
 Moisture content
 Flow properties
 Sieve analysis
b) Post compression Parameters
 Weight Variation
 Hardness
 Thickness
 Dissolution
 Drug content
c) Optimized formulation and reproducible batches.
d) Short term accelerated Stability studies as per ICH guidelines.
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Figure. No. 2 Flowchart plan of work
Lafutidine Domperidone
H2 Blocker Prokinetic agent
Immediate action
(antisecretory and
gastroprotective) Immediate
release
Modified release
Treatment of Gastroesophagal reflux disease (GERD) and Non Ulcer dyspepsia
(NUD)
Patient compliance (once daily dosing)
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DRUG PROFILE
Domperidone: 30, 31, 32,33,34,35
Proprietary name: Motilium®, Motillium , Motinorm and Costi.
Nonproprietary name: Domperidone.
IUPACname:5-chloro-1-(1-[3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-
yl)propyl]piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
Molecular formula: C22H24ClN5O2.
Molecular weight: 425.9.
Appearance: A white or almost white powder.
Solubility: Practically insoluble in water, soluble in dimethyl formamide,Slightly
soluble in alcohol and methanol. (Phr Eu)
Melting point: 242ºC to 248ºC.
Storage: Store protected from light.
BCS Class: Class II drug (Low solubility and high permeability).
Therapeutic category: Used to suppress nausea and vomiting or as a prokinetic
agent.
CLINICAL PHARMACOLOGY OF DOMPERIDONE:
Phamacodynamics and mechanism of action (in detail?):
Domperidone is a specific blocker of dopamine receptors. It speeds
gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and
tool in the study of dopaminergic mechanisms.
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Domperidone acts as a gastrointestinal emptying (delayed) adjunct and
peristaltic stimulant. The gastroprokinetic properties of domperidone are related to
its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric
emptying and decreases small bowel transit time by increasing esophageal and
gastric peristalsis and by lowering esophageal sphincter pressure.
Antiemetic: The antiemetic properties of domperidone are related to its dopamine
receptor blocking activity at both the chemoreceptor trigger zone and at the gastric
level. It has strong affinities for the D2 and D3 dopamine receptors, which are found
in the chemoreceptor trigger zone, located just outside the blood brain barrier, which
among others regulates nausea and vomiting
Domperidone does not cross blood brain barrier as compared to other
dopamine receptor antagonist. Hence it is free of extrapyramidal side effects.
Pharmacokinetics: 49
Absorption
In fasting subjects, Domperidone is rapidly absorbed after oral
administration, with peak plasma concentrations at 30 to 60 minutes. The low
absolute bioavailability of oral
domperidone (approximately 15%) is due to an extensive first-pass metabolism in
the gut wall and liver. Although domperidone`s bioavailability is enhanced in normal
subjects when taken after a meal, patients with gastro-intestinal complaints should
take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the
absorption of domperidone. Oral bioavailability is decreased by prior concomitant
administration of cimetidine and sodium bicarbonate. The time of peak absorption is
slightly delayed and the area under curve (AUC) somewhat increased when the oral
drug is taken after a meal.
Distribution
Oral domperidone does not appear to accumulate or induce its own
metabolism; a peak plasma level after 90 minutes of 21 ng/ml after two weeks oral
administration of 30 mg per day was almost the same as that of 18 ng/ml after the
first dose .Domperidone is 91-93% bound to plasma proteins. Distribution studies
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with radiolabelled drug in animals have shown wide tissue distribution, but low
brain concentration.Small amounts of drug cross the placenta in rats.
Metabolism
Domperidone undergoes rapid and extensive hepatic metabolism by
hydroxylation and N-dealkylation. In vitro metabolism experiments with diagnostic
inhibitors revealed that CYP3A4 is a major form of cytochrome P-450 involved in
the N-dealkylation of domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are
involved in domperidone aromatic hydroxylation.
Excretion
Urinary and fecal excretions amount to 31 and 66% of the oral dose
respectively. The Proportion of the drug excreted unchanged is small (10% of fecal
excretion and approximately 1% of urinary excretion). The plasma half-life after a
single oral dose is 7- 9 hours in healthy subjects but is prolonged in patients with
severe renal insufficiency
Vd: 5.71 l/kg.
Plasma protein binding: 91-93%.
Presystemic metabolism: 85%.
Metablite: 5-Chloro-1, 3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one
Plasma half life: 7 hrs.
Dose: For oral dosage form (tablets).
Treatment of gastrointestinal motility disorders:
Adults—10 milligrams (mg) three to four times daily. Some patients may require
higher doses up to 20 mg three or four times daily.
Nausea and vomiting: Adults—20 milligrams (mg) three to four times daily
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1.2 Lafutidine: 36, 37, 38, 39, 40
IUPAC name : (±)-2-(furfurylsulfinyl)-N-[(Z)-4-[4-(piperidinomethyl)-2-
pyridyl] oxy]-2-butenyl] acetamide
Molecular formula: C22H29N3O4S
Molecular weight: 431.56
Appearance: Lafutidine is a yellowish white crystalline powder with slight peculiar
odour.
Solubility: It is freely soluble in acetic acid, slightly soluble in methanol, slightly
soluble in ethanol (99.5), very slightly soluble in diethyl ether and practically
insoluble in water.
Melting Point: 96-99ºC
Moisture absorbability:
Storage: store protect from light.
BCS class: Class II drug (Low solubility, High permeability)
Therapeutic category: It is a novel Histamine H2 receptor antagonist with a potent
and long lasting anti acid secretary effect and also gastro protective effect.
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CLINICAL PHARMACOLOGY OF LAFUTIDINE:
Pharmacodynamics and mechanism of action:
Lafutidine is protective against experimental gastric lesions even in the
presence of supplementary potent antisecretory therapy, suggesting that it has a
direct gastroprotective effect in addition to its antisecretory properties. Lafutidine
reduces esophageal injury in the gastric acid reflux model, apart from its
antisecretory effect. This protective effect is abolished by selectively ablating
CSAN, antagonism of CGRP and inhibition of NO synthase, suggesting that the
capsaicin pathway is integral to Lafutidine’s protective properties.
Pharmacokinetic Parameters:
Protein binding: 15-20%.
Half life: 2-3hr.
Absorption constant (Ka): 0.956 hr-1
Elimination constant (Kel): 0.329 hr-1
Volume of distribution (Vd): 42.46 lit.
Clearance (Cl): 12.97 l/hr.
Cmax :133.9 (ng/ml).
Tmax : 1.844 hr (article).
Dose:
Gastric and duodenal ulcers.
Adult: 10 mg bid, once after breakfast, once after evening meal or before
sleeping. Adjust dose according to patient's age and symptoms.
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Stomal ulcers
Adult: 10 mg bid, once after breakfast, once after evening meal or before
sleeping. Adjust dose according to patient's age and symptoms.
Gastric mucosal lesions
Adult: 10 mg once daily, after evening meal or before sleeping. Adjust dose
according to patient's age and symptoms.
Pre-anaesthetic medication Adult: 10 mg before sleeping on the day before
operation, and 10 mg 2 hr before introduction of anaesthetic on the day of operation.
1. Excipient Profile:14
2.1. Cellulose, Microcrystalline:
Non-proprietary Names:
BP: Microcrystalline cellulose,
PhEur: Cellulosum microcritsallium,
USPNF: Microcrystalline cellulose
Synonyms: Avicel PH; Celex; cellulosic gel; Celphere; Ceolus sKG; crystalline
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulosel; Vivapur.
Chemical name: Cellulose.
CAS Registry Number: 9004-34-6.
Empirical Formula: [C6H10O5] n.
Molecular Weight: ~36000 Where n=220.
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Structural Formula:
Functional Category: Absorbent, suspending agent, tablet and capsule diluent;
tablet disintegrate.
Application in Pharmaceutical Formulation or Technology:
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compressing process. In addition to its use as binder/diluents,
in tableting. Microcrystalline cellulose is also used in cosmetics and food products.
Solubility: Slightly soluble in 5% W/V Sodium Hydroxide solution; practically
insoluble in water, dilute acids and most organic solvents.
Incompatibilities: Microcrystalline cellulose is incompatible with strong oxidizing
agents. Microcrystalline cellulose also has some lubricant and disintegrates
properties that make it useful.
2.2 Hypromellose
Nonproprietary Names:
BP: Hypromellose,
JP: Hydroxypropyl methylcellulose,
PhEur: Hypromellosum,
USP: Hypromellose.
Synonyms: cellulose, hydroxypropyl methyl ether; hydroxypropyl methylcellulose;
HPMC; Methocel; methylcellulose propylene glycol ether; methyl
hydroxypropylcellulose.
Chemical Name: Cellulose, 2-hydroxypropyl methyl ether.
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CAS Registry Number: [9004-65-3].
Molecular Weight: 10 000–1 500 000.
Structural Formula:
Functional Category: Coating agent; film-former; rate-controlling polymer for
sustained release; stabilizing agent; suspending agent; tablet binder; viscosity-
increasing agent.
Applications in pharmaceutical formulations:
Hypromellose is widely used in oral and topical formulations. In oral
products, hypromellose is primarily used as a tablet binder, in film-coating, and as an
extended-release tablet matrix. Depending upon the viscosity grade, concentrations
of 2–20% w/w are used for film-forming solutions. Lower-viscosity grades are used
in aqueous film- coating solutions, while higher-viscosity grades are used in organic
solvents.
Hypromellose is also used as a suspending and thickening agent, emulsifier,
suspending agent, and stabilizing agent in topical gels and ointments.
Hypromellose at concentrations between 0.45–1.0% w/w may be added as a
thickening agent to vehicles for eye drops and artificial tear solutions. It is also
widely used in cosmetics and food products.
Solubility: Soluble in cold water; practically insoluble in chloroform, ethanol (95%)
and ether, but soluble in mixtures of ethanol and dichloromethane, mixtures of
methanol and dichloromethane, and mixtures of water and alcohol.  Certain grades
of hypromellose are soluble in aqueous acetone solutions, mixtures of
dichloromethane and propan-2-ol, and other organic solvents.
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Incompatibilities: Hypromellose is incompatible with some oxidizing agents.
2.3 Magnesium Stearate
Nonproprietary Names:
BP: Magnesium stearate,
JP: Magnesium Stearate,
PhEur: Magnesii stearas,
USPNF: Magnesium stearate.
Synonyms: Magnesium octdecanoate; octadeconoic acid, magnesium salt; striate
acid, magnesium salt.
Chemical name: Octadeconoic acid magnesium salt.
CAS Registry Number: [557-04-0].
Empirical Formula: C36H70MgO4.
Molecular Weight: 591.34.
Structural Formula: [CH3 (CH2)16COO]2 Mg.
Structural Formula:
Functional Category: Tablet and capsule lubricant.
Application in Pharmaceutical Formulation or Technology:
agnesium striate is widely used in cosmetics, food and pharmaceutical
formulation. It is primarily used as a lubricant in capsule and tablet manufacture at
concentration between 0.25% and 5% w/w. It is also used in barrier creams.
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Solubility: Practically insoluble in ethanol, ether and water; slightly soluble in warm
benzene and warm ethanol (95%).
Incompatibilities: Incompatible with strong acids, alkalies, and iron salts. Avoid
mixing with strong oxidizing materials. Magnesium stearate cannot be used in
products containing aspirin, some vitamins, and most alkaloidal salts.
2.4 Croscarmellose sodium:
Non proprietary names:
BP: Croscarmellose Sodium
JP: Croscarmellose Sodium
PhEur: Croscarmellose Sodium
USP-NF: Croscarmellose Sodium
Synonyms:
Ac-Di-Sol, Cross-linked Carboxy methyl cellulose (CMC) Sodium, Explocel,
Modified Cellulose Gum, Nymcel ZSX, Primellose, Vivosol.
Structural formula;
d
Structural Formula:
Chemical Name:
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Cellulose,
Applications in Pharmaceutical Formulation or Technology:
As a disintegrant for tablets (wet granulation and direct compression), capsules and
granules at a concentration of 2-5%.
Table.No.2 :Uses of Croscarmellose Sodium.
Use Concentration (%)
Emulsifying agent 0.25 – 1.0
Gel – forming agent 3.0 – 6.0
Injections 0.05 – 0.75
Oral Solutions 0.1 – 1.0
Tablet Binder 1.0 – 6.0
2.5 Colloidal silicon dioxide (Arosil):
Non Proprietary Names:
BP: Colloidal Anhydrous Silica
JP: Light Anhydrous Silicic Acid
PhEur: Silica, Colloidal Anhydrous
USP-NF: Colloidal Silicon Dioxide
Synonyms:
Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica, fumed silica, light
anhydrous silicic acid, silicic anhydride, silicon dioxide fumed, Wacker HDK.
Chemical Name and CAS Registry Number: Silica [7631-86-9].
Empirical Formula and Molecular Weight: SiO2, 60.08
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Functional Category:
Adsorbent, anticaking agent, emulsion stabilizer, glidant, suspending agent,
tablet disintegrant, thermal stabilizer, viscosity-increasing agent.
Applications in Pharmaceutical Formulation or Technology:
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and
food products, Colloidal silicon dioxide is also used as a tablet disintegrant and as an
adsorbent dispersing agent for liquids in powders. Colloidal silicon dioxide is
frequently added to suppository formulations containing lipophilic excipients to
increase viscosity, prevent sedimentation during molding and decrease the release
rate.
Table.No.3: Uses of colloidal silicon dioxide.
Use Concentration (%)
Aerosols 0.5 – 2.0
Emulsion stabilizer 1.0 – 5.0
Glidant 0.1 – 0.5
Suspending and thickening agent 2.0 – 10.0
2.6 Isopropyl Alcohol
Nonproprietary Names:
BP: Isopropyl alcoh,
JP: Isopropanol,
PhEur: Alcohol isopropylicus,
USP: Isopropyl alcohol
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Synonyms: Dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; sec-propyl
alcohol.
Chemical Name: Propan-2-ol.
CAS Registry Number: [67-63-0].
Empirical Formula: C3H8O.
Molecular Weight: 60.1.
Structural Formula
Functional Category: Disinfectant; solvent.
Applications in Pharmaceutical Formulation or technology:
Applications Isopropyl alcohol is used in cosmetics and pharmaceuticals as a solvent.  Isopropyl
alcohol is used as a solvent for tablet film-coating and tablet granulation. Isopropyl
alcohol used as a topical disinfectant.
Solubility: Miscible with benzene, chloroform, ethanol, ether, glycerin, and water.
Soluble in acetone; insoluble in salt solutions.
Incompatibilities: Incompatible with oxidizing agents such as hydrogen peroxide
and nitric acid, which cause decomposition.  Isopropyl alcohol may be salted out
from aqueous mixtures by the addition of sodium chloride, sodium sulfate, and other
salts, or by the addition of sodium hydroxide.
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2.7 Lactose monohydrate:
1. Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucose, (alpha)-Lactose, Milk Sugar,
Milk Sugar, Lactose Monohydrate.
2. Chemical Name:
Lactose, Monohydrate.
3. Chemical Formula:
C12H22O11. H2O
5. Molecular Weight: 360.3.
Table.No.4: Typical Properties of Lactose Monohydrate
Properties Range
pH 5.0 -7.5
Angle of repose 40 o
Bulk density 0.22 g/cm3
Tapped density 0.45 g/cm3
True density 0.435-0.562 g/cm3
Melting point 214C (417F)
Specific gravity 1.53
6. Applications in Pharmaceutical Formulation or Technology:
Lactose Monohydrate is widely used in pharmaceuticals, primarily as a
diluent in oral tablet and capsule formulations where it is used in both wet-
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granulation and direct compression processes. In addition to it has some lubricant
and disintegrant properties that make it useful in tabletting.
Table.No.5: Uses of Lactose monohydrate
Use Concentration (% w/w)
Adsorbent 20-90
Antiadherants 5-15
Capsule binder/diluents 20-90
Tablet disintegrants 5-15
Tablet binder/diluents 20-90
7. Solubility:
Soluble in water.
8. Description:
Lactose Monohydrate is a purified, white to off-White, odorless, tasteless,
crystalline powder composed of porous particles. It is commercially available in
different particle sizes and moisture grades that have different properties and
applications.
2.7 Starch
1. Nonproprietary Names:
BP: Maize starch, Potato starch, Rice starch, Wheat starch, JP: Corn starch,
PhEur: Maydis amylum (maize starch), USPNF: Corn starch Tapioca
2. Synonyms:
Amido, amidon, amilo, amylum, Aytex P, C*PharmGel, Fluftex W, Instant Pure-
Cote, Melojel, Meritena, Paygel 55.
3. Chemical Name and CAS Registry Number:
Starch, [9005-25-8].
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4. Empirical Formula and Molecular Weight:
(C6H10O5)n 50, 000–1,60, 000.
Where n = 300–1000.
5. Functional Category:
Glidant; tablet and capsule diluents; tablet and capsule disintegrants; tablet
binder.
6. Structural Formula:
7. Applications in Pharmaceutical Formulation or Technology:
Starch is used as an excipient, primarily in oral solid-dosage formulations
where it is utilized as a binder, diluent, and disintegrant.
As a diluent, starch is used for the preparation of standardized triturates of
colorants or potent drugs to facilitate subsequent mixing or blending processes in
manufacturing operations. Starch is also used in dry-filled capsule formulations for
volume adjustment of the fill matrix.
In tablet formulations, freshly prepared starch paste is used at a concentration
of 5–25% w/w in tablet granulations as a binder. Selection of the quantity required in
a given system is determined by optimization studies, using parameters such as
granule friability, tablet friability, hardness, disintegration rate, and drug dissolution
rate.
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Starch is one of the most commonly used tablet disintegrants at
concentrations of 3–15% w/w. However, unmodified starch does not compress well
and tends to increase tablet friability and capping if used in high concentrations. In
granulated formulations, about half the total starch content is included in the
granulation mixture and the balance as part of the final blend with the dried
granulation. Also, when used as a disintegrant, starch exhibits type II isotherms and
have a high specific surface for water sorption.
8. Description:
Starch occurs as an odorless and tasteless, fine, white-colored powder
comprising very small spherical or ovoid granules whose size and shape are
characteristic for each botanical variety
9. Solubility:
Practically insoluble in cold ethanol (95%) and in cold water. Starch
swells instantaneously in water by about 5–10% at 37°C. Polyvalent cations
produce more swelling than monovalent ions, but pH has little effect.
2.8 Citric acid monohydrate
1. Nonproprietary Name:
BP: Citric Acid Monohydrate
JP: Citric Acid Hydrate
PhEur: Citric Acid Monohydrate
USP: Citric Acid Monohydrate.
2. Synonyms:
Acidum citricum monohydricum; E330; 2-hydroxypropane-1,2,3-tricarboxylic acid
monohydrate.
3. Chemical Name :
2-Hydroxy-1, 2, 3-propanetricarboxylic acid monohydrate.
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4. Empirical Formula and Molecular Weight:
C6H8O7H2O , 210.14
5 Structural Formula:
6. Functional Category:
Acidifying agent; antioxidant; buffering agent; chelating agent; flavor enhancer;
preservative.
7. Applications in Pharmaceutical Formulation or Technology:
Citric acid (as either the monohydrate or anhydrous material) is widely used in
pharmaceutical formulations and food products, primarily to adjust the pH of
solutions. It has also been used experimentally to adjust the pH of tablet matrices in
enteric-coated formulations for colon-specific drug delivery. Citric acid
monohydrate is used in the preparation of effervescent granules, while anhydrous
citric acid is widely used in the preparation of effervescent tablets.Citric acid has
also been shown to improve the stability of spray-dried insulin powder in inhalation
formulations.
In food products, citric acid is used as a flavor enhancer for its tart, acidic taste.
Citric acid monohydrate is used as a sequestering agent and antioxidant synergist;
see Table I. It is also a component of anticoagulant citrate solutions. Therapeutically,
preparations containing citric acid have been used to dissolve renal calculi.
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2.8 Povidone:
1. Nonproprietary Names:
BP: Povidone
JP: Povidone
PhEur: Povidone
USP: Povidone
2. Synonyms:
E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone;
polyvinylpyrrolidone; povidonum; Povipharm; PVP; 1- vinyl-2-pyrrolidinone
polymer.
3. Chemical Name:
1-Ethenyl-2-pyrrolidinone homopolymer
4. Empirical Formula and Molecular Weight:
(C6H9NO)n ; 2500–3 000 000
The USP 32 describes povidone as a synthetic polymer consisting essentially
of linear 1-vinyl-2-pyrrolidinone groups, the differing degree of polymerization of
which results in polymers of various molecular weights. It is characterized by its
viscosity in aqueous solution, relative to that of water, expressed as a K-value, in the
range 10–120.
Table.No.6: Approximate molecular weights for different grades of Povidone
K-value Approximate molecular
weights
12 2500
15 8000
17 10000
25 30000
30 50000
60 400000
90 1000000
120 300000
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5. Structural formula:
6. Functional Category:
Disintegrant; dissolution enhancer; suspending agent; tablet binder.
7. Applications in Pharmaceutical Formulation or Technology:
Although povidone is used in a variety of pharmaceutical formulations, it is
primarily used in solid-dosage forms. In tableting, povidone solutions are used as
binders in wet-granulation processes. Povidone is also added to powder blends in the
dry form and granulated in situ by the addition of water, alcohol, or hydroalcoholic
solutions. Povidone is used as a solubilizer in oral and parenteral formulations, and
has been shown to enhance dissolution of poorly soluble drugs from solid-dosage
forms.(4–6) Povidone solutions may also be used as coating agents or as binders
when coating active pharmaceutical ingredients on a support such as sugar beads.
Povidone is additionally used as a suspending, stabilizing, or viscosity-increasing
agent in a number of topical and oral suspensions and solutions. The solubility of a
number of poorly soluble drugs may increase by mixing with povidone.
8 Uses:
Table.No.7: Uses of Povidone
Use Concentration (%)
Carrier for Drug 10-25
Dispersing agent Up to 5
Eye drops 2-10
Suspending agent Up to 5
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EXPERIMENTAL WORK
1. Characterisation of Active pharmaceutical Ingredient (API):
a) Organoleptic evaluation:
This includes recording of colour, odour, and taste of the drug using
descriptive terminology. Record of colour of early batches is very useful in
establishing appropriate specifications for later production. Drugs generally have a
characteristic odours and tastes. Unpleasant ones are masked later during
formulation.
Table.No.8: APIs Organoleptic evaluation results
Tests Lafutidine Domperidone
Colour Yellowish white White
Odour Peculiar odour No odour
1. Bulk drug Characterisation:
a) Flow properties:
Angle of repose: 23
Angle of repose has been used in several branches of science to characterize
flow properties of solids. Angle of repose is a characteristic related to
interparticulate friction or resistance to flow between particles. This is the maximum
angle possible between surface of pile of powder or granules and the horizontal
plane.
tan  = h / r  …………………………………………….(1)
 = tan –1 h / r ………………………………………….. (2)
Where,  = angle of repose, h = height of heap, r = radius of base of heap circle.
A funnel was fixed at a height approximately 2-4 cm over the platform. The
loose powder was slowly passed along the wall of funnel, till the tip of powder cone
so formed just touched the tip of funnel stem. Angle of repose was then determined
by measuring the height of the cone of powder and radius of the circular base of
powder heap.
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Table.No.9: Flow properties and corresponding angles of repose.
Flow property Angles of repose
Excellent 25-30
Good 31-35
Fair-aid not needed 36-40
Passable- may hang up 41-45
Poor-must agitate, vibrate 46-55
Very poor 56-65
Very, very poor >66
Density analysis: 24
The volume of powder packing was determined on an apparatus consisting
of a graduated cylinder mounted on a mechanical tapping device that has a specially
cut rotating cam. An accurately weighed sample of powder was carefully added to
the cylinder with the aid of a funnel. Initial volume of powder was noted and the
sample subjected to tapping (500, 750 or 1250 tapings) until no further reduction in
volume was noted or the percentage of difference in volume was not more than 2 %.
A sufficient number of taps should be employed to assure reproducibility for the
material in question. The tapings should not produce particle attrition or a change in
the particle size distribution of the material being tested.
Weight in gm of sample
Bulk density = g/ml………………… (3)
Volume occupied by sample in ml
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Tapped density:
Tapped density is determined by placing a graduated cylinder
containing a known mass of drug on a mechanical tapper apparatus which is
operated for fixed number of taps (~ 100) until a powder bed volume has reached the
minimum. Using the weight of drug in cylinder and tapped volume, the tapped
density is determined.
Weight of powder in gm
Tapped density = gm/m l ……… (4)
Tapped volume in ml
Compressibility index: 25
A useful empirical guide is given by Carr's compressibility index.
Tapped – Poured density
Carr’s index (%) = X 100…………. (5)
Tapped density
Tapped density
Hausner ratio = ………………………….(6)
Bulk density
Table.No.10: Scale of flow ability
Compressibility index (%) Flow character Hausner ratio
10 Excellent 1.00-1.11
11-15 Good 1.12-1.18
16-20 Fair 1.19-1.25
21-25 Passable 1.26-1.34
26-31 Poor 1.35-1.45
32-37 Very poor 1.46-1.59
> 38 Very, very poor > 1.60
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Table.No.11: Flow properties of Active pharmaceutical ingredient (API)
Flow properties Lafutidine Domperidone
Bulk density (gm/ml) 0.4615 0.259
Tapped density (gm/ml) 0.545 0.454
Carr’s Compressibility index (%) 18.17 42.85
Hausner ratio 1.18 1.750
The preliminary micromeritic studies carried out on drug suggest that
Domperidone posseses very poor flow property. Hence the method of choice for
formulation of drug was wet granulation.Once formulated as granules; the flow
property of drug was increased.
a) Particle size determination:
The procedure involves the electromagnetic sieve shaking of the sample
through the series of successively arranged sieves (sieve no. 20, 30, 60, 80 and
100 and receiver), and weighing of the portion of the sample retained on each
sieve and  calculating percentage retained on each sieve.
Particle size was determined by sieve method.
Weight of sample taken: 50 g.
Table.No.12: Sieve analysis of Lafutidine:
Sieve No. Qty. retained (g) Percentage
20 # retained 0.566 g 1.132 %
40 # retained 2.8096 g 5.62 %
60 # retained 0.8822 g 1.7644 %
80 # retained 0.3514 g 0.703 %
100 # retained 0.2628 g 0.5256 %
Fines (Below 100 #) 45.128 g 90.26 %
Total 50.00 g 100.00 %
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Table.No.13: Sieve analysis of Domperidone
Sieve No. Qty. retained (g) Percentage
20 # retained 27.678 g 55.35
40 # retained 15.998 g 31.98
60 # retained 3.22 g 6.44
80 # retained 1.14 g 2.28
100 # retained 1.09 g 2.18
Fines (Below 100 #) 1.128 g 2.25
Total 50.00 g 100.00 %
Particle size analysis of Lafutidine by Malvern
Figure.No.3: Graph showing Particle size distribution by Malvern technique
D (0.9): 61.728 μm (90 % of the particles were 61.728 μm or above)
D (0.5): 19.664 μm (50 % of the particles were 19.664 μm or above)
D (0.1): 6.966 μm (10 % of the particles were 6.966 μm or above)
f) Moisture content:
Mositure content studies of API are important as the moisture if absorbed by
the drug can play a major role in drug’s degradation pathway.
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Also the absorbed moisture may sometimes result in the degradation or none
functioning of the entire product due to its effect on therapeutic activity of drug and
also on the drug excipient incompatibility.
Table.No.14: Hygroscopic criteria as per European Pharmacopoeia
S.
No.
Sample is
Criteria as per European Pharmacopoeia
(When Sample is exposed to 80+ 2 % RH at 25○C+1○C for 24 hours)
1 Deliquescent Sufficient water is absorbed to form a liquid
2
Very
Hygroscopic
Increase in mass is equal to or greater than 15 %
3 Hygroscopic Increase in mass is less than 15 % and equal to or greater than 2 %
4
Slightly
Hygroscopic
Increase in mass is less than 2 % and equal to or greater than 0.2 %
2. Preparation Of calibration curve of Lafutidine and Domperidone:
Linearity of Lafutidine and Dmperidone was performed using the standard
solution in the range of 14.50mcg/ml to 26.93mcg /ml of Lafutidine ( ie 70 to 130 %
of Standard concentration) and 42.09mcg/ml to 78.17mcg/ml of Domperidone (70
to 130 % of Standard concentration). Standard preparation: Weigh accurately about
20mg Lafutidine working standard and 60mg of Domperidone working standard,
transfer into a 100ml volumetric flask, add 70ml of methanol, sonicate to dissolve
and make up the volume with methanol.
A graph was plotted with concentration on X axis and mean peak areas on y axis for
Lafutidine and Domperidone and correlation coefficient was determined.
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Table.No.15: Linearity of Response (Lafutidine)
Sr no Concentration of Lafutidine in mcg/ml Mean Peak areas
1 14.50 156611
2 16.57 181679
3 18.64 202751
4 20.71 227669
5 22.78 247176
6 24.85 270177
7 26.93 288577
Standard Curve of Lafutidine.
Figure.4: Standard Curve of Lafutidine.
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Table.16: Linearity of response (Domperidone)
Sr no Concentration of Domperidone in mcg/ml Mean Peak areas
1 42.09 995024
2 48.11 1153687
3 54.12 1287416
4 60.13 1446537
5 66.15 1563481
6 72.16 1706704
7 78.17 1829442
Standard curve of Domperidone
Figure 5: Standard curve of Domperidone
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3. Drug-Excipient Compatibility:25
Knowledge of the interaction of drugs and excipients is essential in
the initial formulation of a product. It may also be necessary later on during
processing scale-up, when problems arise, to determine if incompatibilities exist
which affect manufacturing or stability. Drug-excipient interactions are often
directly related to the moisture present in one or another of the components or to the
humidity to which the formulation is exposed during processing or storage.
These studies are always carried out at accelerated temperature and humidity
conditions, even though it must be recognized that some interactions are physical
and not chemical and that accelerated aging may not be predictive. Tests for
excipient drug interactions are usually conducted on blends of the pure drug and
excipient in ratios similar to those in the final dosage form. For example, excipient
to drug ratios are higher for filler-binders than for lubricants and disintegrating
agents. These studies are often performed with the help of a factorial or fractional
factorial experimental design.26
Powders are physically mixed and may be granulated or compacted to accelerate any
possible interaction. Samples can be exposed in open pans or sealed in bottles or
vials to mimic product packaging. Evaluation of samples includes:
1. Visual inspection for changes in colour or texture.
2. Both HPLC and TLC are commonly employed with unstressed samples being
used as controls. In general, only qualitative results are important initially.
3. Differential thermal analysis is applied and the appearance or disappearance of
one or more peaks is noted. Isothermal microcalorimetry can also be employed as
well as a thermal activity monitor (TAM) technique.
Compatibility studies are essential in characterizing both raw materials and
finished formulations. It has been argued that binary drug-excipient screening
studies are inefficient, unrealistic, and ignore processing variables. A better
approach may be to carefully select potential excipients based on known chemistry
and published compatibility data, and perform miniformulation stability studies.27
On the basis of Literature survey, Domperidone was found to be compatible with
following excipients:
Lactose , Pregelatinised Maize Starch , Microcrystalline Cellulose , Sodium
Starch Glycollate Type A , Magnesium Stearate , Titanium dioxide (E171) ,
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Hypromellose , Macrogol , Maize starch, microcrystalline cellulose, Povidone,
Propylene glycol, silicon dioxide , Polysorbate 20, Lactose monohydrate , Sodium
lauryl sulphate,  Silica colloidal anhydrous .29
On the basis of Literature survey, Lafutidine was found to be compatible
with following excipients:
Lactose, microcrystalline cellulose, corn starch, light anhydrous silica ,
croscarmellose sodium, hydroxypropylcellulose, talc, magnesium stearate,
hydroxypropyl methylcellulose 2910, macrogol 6000, titanium oxide, and carnauba
wax .28
The drug excipient compatibility study was carried out by following two methods:
1) Accelerated stability condition.
2) DSC studies.
The drug and individual excipient mixture of all excipients were taken in the
ratio given in tables below. The prepared composition was passed through 30# sieve for
uniform mixing of the composition. 3gm of the mixture was filled in 10ml clear glass vials.
The two methods employed are open vial and closed vial with HDPE stopper. The
samples were observed for physical changes in 15 days and 1 Month duration.
Differential scanning calorimetry or DSC is a thermo analytical technique in
which the difference in the amount of heat required to increase the temperature of a
sample and reference is measured as a function of temperature. Both the sample and
reference are maintained at nearly the same temperature throughout the experiment.
Generally, the temperature program for a DSC analysis is designed such that the
sample holder temperature increases linearly as a function of time. The reference
sample should have a well-defined heat capacity over the range of temperatures to
be scanned.
The result of a DSC experiment is a curve of heat flux versus temperature or
versus time. The melting point of Lafutidine is 96-99°and that of Domperidone is
244-248°C.
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4. Analytical method:
4.1 Assay by HPLC: Determination of content of Lafutidine and
Domperidone.
Preparation of 6.8 phosphate buffer solution:
Dissolve 4.45g of disodium hydrogen phosphate dihyadrate
(Na2HPO4,2H2O) in 1000ml of water. Adjust pH to 6.5 with orthophosphoric acid.
Preparation of mobile phase: Prepare a mixture of pH 6.8 phosphate buffer
solution and Acetonitrile in ratio of 70:30.Filter and degas.
Standard preparation:
Weigh accurately about 20mg Lafutidine working standard and  60mg of
Domperidone working standard , transfer into a 100ml volumetric flask, add 70ml of
methanol, sonicate to dissolve and make up the volume with methanol. Further
dilute 5ml to 50ml with mobile phase.
Assay preparation:
Weigh and transfer the content of 20 capsules and powder the content.
Weigh accurately quantity of powder containing the equivalent of about 30mg of
Domperidone into a 100ml volumetric flask. Add 70ml of methanol sonicate for
15minutes with intermittent shaking and make up the volume with methanol. Filter
through 0.45µ Nylon membrane filter or 0.45µ PVDF membrane filter. Further
dilute 5ml to 25ml mobile phase.
Chromatographic conditions:
Column: Octadecylsilane column, 250 mm X 4.6mm, 5µ (XTerra or equivalent)
Flow rate: 1.0ml/ min
Wavelength: 276nm
Injection volume: 20µl
Column Temperature: 30ºC
Run time: 30 minutes
Procedure:
Wash the column and equilibrate with mobile phase. Seperately inject equal
volumes (20µl) of standard preparation (five replicate injections) and assay
preparation (Duplicate injection) into the chromatograph. The system suitability
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parameters should be met. From the peak responses, calculate the content of
Domperidone and Lafutidine in the sample.
Calculation:
Content of Lafutidine
% Content of Lafutidine = AT  x W std x 5 x 100 x 25x P x Avg filled weight X
100
As 100     50   Wtest 5    100      L.C
AT = Average of the area counts of the Lafutidine peak obtained from the
chromatograms of                                       the assay preparation.
As =  Average of the area of the Lafutidine peak obtained from the chromatograms
of the standard preparation.
Wstd = Weight of the Lafutidine working standard taken in mg.
W test = Weight of sample taken in mg.
P = % Potency of Lafutidine working standard.
L.C= Label claim of Lafutidine in mg.
Content of Domperidone
% Content of Domperidone=   AT  x W std  x 5 x 100 x 25x P  x  Avg filled weight X
100
As 100     50   Wtest 5    100      L.C
AT = Average of the area counts of the Domperidone  peak obtained from the
chromatograms of  the assay preparation.
As = Average of the area of the Domperidone peak obtained from the
chromatograms of the standard preparation.
Wstd = Weight of the Domperidone working standard taken in mg.
W test = Weight of sample taken in mg.
P = % Potency of Domperidone working standard.
L.C= Label claim of Domperidone in mg.
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4.2 Dissolution Method
Following method was applied through out the dissolution study of the
product.
Dissolution was carried out initially in 0.1N HCL for 2hrs followed by 6.8
phosphate buffer for 24hrs.
4.2.1 Dissolution in acidic media (0.1N HCL)
Table 17: Dissolution Parameters
Dissolution medium 0.1 N HCl
Dissolution medium volume 900 ml
Apparatus USP - 2 (paddle)
Speed 100rpm
Temperature 37±5oC
Sampling time interval 30mins,1hr, 2hr
Standard preparation
Weigh accurately about 77mg of Domperidone maleate working standard
and 20mg of Lafutidine working standard into a 100ml volumetric flask, add
80ml methanol.Sonicate to dissolve and make up the volume with methanol. Further
dilute 5ml of this solution to 100ml with dissolution media.
Test preparation
Transfer 900ml of dissolution medium in the vessel carefully and allow
equilibrating to a temperature of 37±0.5ºC. Place one capsule in each of the vessels
and operate the apparatus at 100 rpm. Withdraw 10ml of the sample from each of
the dissolution vessel at given time point and filter through 0.45µ membrane filter.
Note: After completion of dissolution in (0.1 N HCl, acidic medium) (2 hrs),
carefully remove the dissolution medium without disturbing the capsules. Use the
same capsules for further dissolution in phosphate buffer pH 6.8.
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Procedure
Wash the column and equilibrate with mobile phase. Seperately inject equal
volumes of the standard preparation (five replicate injections) and test preparation
(singe injection) into the chromatograph. Record the chromatograms and measure
the peak responses for Lafutidine and Domperidone. The system suitability
parameters should be met. From peak responses, calculate the content of Lafutidine
and Domperidone in the sample.
Table 18: component Retention time
Sr no Component name Retention time
1 Lafutidine 7.0 minutes
2 Domperidone 15.0 minutes
Calculation
% Domperidone released = AT x W std  x 5 x 900 x P  x 100    X F
As 100 100 1     100 L.C
Where,
AT = Area counts of the Domperidone peak obtained from the chromatograms of
the test preparation.
As = Average of the area of the Domperidone peak obtained from the
chromatograms of the standard preparation.
Wstd = Weight of the Domperidone working standard taken in mg.
P = % Potency of Domperidone working standard.
L.C= Label claim of Domperidone in mg/tab.
F= Conversion factor of Domperidone maleate to Domperidone 0.7858.
Correction factor= % Domperidone released (uncorrected) x volume of dissolution
media sampled or replaced / total volume of dissolution media.
% Domperidone released (corrected) (in 0.1N Hydrochloric acid stage)= %
Domperidone released (uncorrected) + sum of correction factor of all previous
intervals.
% Lafutidine released =   AT  x W std  x 5 x 900 x P       X L.C
As 100   100   1 100
Where,
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AT = Area counts of the Lafutidine peak obtained from the chromatograms of  the
test preparation.
As = Average of the area of the Lafutidine peak obtained from the chromatograms of
the standard preparation.
Wstd = Weight of the Lafutidine working standard taken in mg.
P = % Potency of Lafutidine working standard.
L.C= Label claim of Lafutidine in mg/tab.
Correction factor= % Lafutidine released (uncorrected) x volume of dissolution
media sampled or replaced / total volume of dissolution media.
% Lafutidine released (corrected) (in 0.1N Hydrochloric acid stage)= % Lafutidine
released (uncorrected) + sum of correction factor of all previous intervals.
3.2.2 Dissolution in Phosphate Buffer pH 6.8
Table 19: Dissolution Parameters
Dissolution Medium Phosphate buffer pH 6.8 (900ml)
Apparatus USP type II
Speed 100 rpm
Time 2,4,6,8,10,12,14,16,18 hrs
Temperature 37±5 ºC
Preparation of Phosphate buffer pH 6.8
Dissolve 68 gm of Potassium dihydrogen phosphate in10000 ml of water and
adjust the pH to 6.8 with 10%w/w sodium hydroxide solution.
Standard preparation
Weigh accurately about 77g of Domperidone maleate working standard and
allow the medium to equilibrate to temperature of 37± 5º C. All the six capsules of
acid dissolution medium continue in pH 6.8 phosphate buffer, place one capsule in
each of the vessels and operate the apparatus at 100 rpm. Withdraw 10ml of the
sample from each dissolution vessel and filter through 10µ membrane filter of
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instrument or withdraw 10ml of the sample manually from each dissolution vessel at
given time interval and filter through 0.45µ membrane filter.
Procedure
Wash the column and equilibrate with mobile phase.Seperately inject equal
volumes (20µl) of the standard preparation (five replicate injections) and test
preparation (single injection) into chromatograph .Record the chromatograms and
measure the peak responses for Domperidone. The system suitability parameters
should be met. From the peak responses, calculate the content of Domperidone in
sample.
Calculation
% Domperidone released =   AT  x W std  x 5 x 900 x P  x  100    X F
As 100   100   1     100   L.C
Where,
AT = Area counts of the Domperidone peak obtained from the chromatograms of the
test preparation.
As = Average of the area of the Domperidone peak obtained from the
chromatograms of the standard preparation.
Wstd = Weight of the Domperidone working standard taken in mg.
P = % Potency of Domperidone working standard.
L.C= Label claim of Domperidone in mg/tab.
F= Conversion factor of Domperidone maleate to Domperidone 0.7858.
Correction factor= % Domperidone released (uncorrected) x volume of dissolution
media sampled or replaced / total volume of dissolution media.
% Domperidone released (corrected) (in 0.1N Hydrochloric acid stage)= %
Domperidone released (uncorrected) + sum of correction factor of all previous
intervals.
% Total Domperidone released = % Domperidone released (corrected in acid stage)
+ % Domperidone released (corrected) (in pH 6.8 phosphate buffer stage).
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5. Formulation and development
5.1)  Materials
The active pharmaceutical ingredient (API) , the excipients and coating
material used for the development of the product are given in following table.
Table 20: Materials used for the Product development
Sr. No. Name Suppliers of Material
1 Domperidone Vasudha Pharma.
2 Lafutidine Optimus Pharma Ltd.
3 Methocel K4M Indchemie Health specialities pvt ltd.
4 HPMC 15 cps Vasudha Pharma.
5 Povidone K-30 Alkem Laboratories Ltd.
6 Colloidal anhydrous silica Cabot Sannar Ltd.
7
Microcrystaline cellulose
(Avicel PH 102) Sigachi Chloro Chemicals ltd.
8 Lactose DCL Optimus Pharma Ltd.
9 Pregelatinised  Maize starch Cabot Sannar Ltd.
10 Citric acid monohydrate Alkem Laboratories Ltd.
11
Crosscarmellose sodium
(Ac-di-Sol) Optimus Pharma Ltd.
12 Magnesium stearate Amishi Drug & Chemical .
13 Isopropyl alcohol Merck.
14 Purified water Alkem Laboratories Ltd.
15 Instacoat A05D00512 Ideal Cures Ltd.
16 Isopropyl alcohol Merck.
17 Methylene chloride Rankem (Ranbaxy Ltd).
Coating material (product code number) contains: Talc, HPMC E-5, indigo carmine,
PEG 6000.
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5.2) Equipments used:
Table 21: list of equipments used
Sl. No. Equipments Manufacturer
1 Tablet compression machine
Cadmach (16 station, single rotary,
compression machine, with ‘D’ tooling
setup)
2 Punch Set (6.5 X 6.5 SC, plain onboth sides) Parle Global Punching tools Pvt. Ltd.
3 Tablet coating machine Pharma R&D Coater
4 Rapid mixing granulator (RMG) Kevin
5 Dissolution apparatus Electrolab (TDT-08L)
6 HPLC apparatus
Dionex (P-680),Waters (2695), Agilent
(1100)
7 UV-Visible spectrophotometer
Jasco V 530 & Perkin Elmer
(Lambda25)
8 Differential scanning calorimeter Mettler Toledo (DSC-822e)
9 Rapid dryer Retsch (TG-100)
10 Electromagnetic sieve shaker Electrolab (EMS-8)
11 Loss on drying apparatus Mettler Toledo (HB 43)
12
Capsule Filling machine (semi
automatic) Pam Glatt
13 Hardness tester Monsanto Hardness Tester
15 Density  apparatus Electrolab  (ETD-1020)
16 Blender Pretime – D
17 Mechanical shaker Skan
18 Roche friabilator USP Electrolab (EF-1W)
19 Vernier caliper Mitutoyo (absolute digimatic)
20 Digital pH meter Lab india
21 Digital weighing balance Mettler Toledo (AB 204-S)
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The sustained release Tablet of Domperidone is not official in any of the
Pharmacopoeia; hence the present product development strategy was aimed by
developing a tentative specification for 24 hrs release, based on the pharmacokinetic
parameters as well as the results obtained from few of the trial batches. The release
profile decided is as follows:
Table 22:: Tentative Release profile
Time (In Hours) % Domperidone Release
2nd Hour 30-40%
4th Hour 40-60%
8th Hour NLT 60%
12th Hour 60-70%
18th Hour 70-85%
24th Hour NLT 85%
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The formulation work was carried out as follows
Formulation and development
Selection of process Selection of Excipients
Wet granulation
Selection of Polymers
Selection of diluents
Selection of binders
Selection of disintegrant
Selection of Lubricants
Optimization of final formula
Stability studies
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5.3) Formulation Methods
5.3.1) Formulation of Lafutidine blend
Table 23: Formulation of Lafutidine blend
Sr
no Ingredients
Batch 001
Qty
(mg/capsule)
Batch 002
Qty
(mg/capsule)
Batch003
Qty
(mg/ capsule)
1 Lafutidine 10.04 10.04 10.04
2 Lactose DCL 21 129.50 129.5 127.46
3
Microcrystalline
Cellulose
( MCC PH 102)
98.46 98.46 100
4
Crosscarmellose
sodium
( Ac-Di-Sol)
- 10 10
5
Sodium starch
glycollate (SSG)
10 - -
6
Colloidal Silicon
Dioxide
(Aerosil-200)
1 1 1.5
7
Magnesium
stearate
1 1 1
Total weight (mg) 250 250 250
Steps involved in the formulation of Lafutidine blend are as follows:
1) Sifting
Weighed quantity of Lafutidine, Lactose DCL 21, Microcrystalline cellulose pH
101, Crosscarmellose sodium was passed through 30 # sieve.
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2) Dry blending
The materials of step 1 were mixed together in double cone blender for 10
minutes and were again passed through 30# sieve.
3) Prelubrication
Weighed quantity of Aerosil 200 was passed through 30 # sieve and was added
to material of step 2 and mixed in the blender for 15 minutes.
4) Lubrication
Weighed quantity of Mg stearate was passed through 60# sieve and was added to
material of step no 6 in the blender and further mixing was carried out for 5
minutes.
5.3.2) Formulation of Domperidone IR tablets:
Table 24 Formulation of Domperidone IR tablets.
Sr
No Ingredient
Batch 001
Qty
(mg/tab)
Batch 002
Qty
(mg/tab)
Batch 003
Qty
(mg/tab)
1 Domperidone 10.06 10.06 10.06
2 LactoseMonohydrate 41 35 40
3
Microcrystalline
Cellulose
(PH 101)
20.04 16.94 16.94
4 Maize Starch 5 15 10
5
Polyvinyl
pyrollidone  (PVP
K 30)
3 1 1
6 PregelatinisedMaize starch 10 0 0
7 Sodium Starchglycollate (SSG) 0 11 11
8
Colloidal silicon
dioxide
(Aerosil 200)
0.45 0.5 0.5
9 Magnesium
stearate 0.45 0.5 0.5
10 Purified Water 40ml 40ml 40ml
Total weight(mg) 90 90 90
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Steps involved in the formulation of Domperidone IR tablets are as follows:
1) Sifting
Weighed quantity of Domperidone, Lactose Monohydrate and Microcrystalline
cellulose pH 101 was passed through 30 # sieve.
2) Dry mixing
The materials of step 1 were mixed together in RMG for 10 minutes and were
again passed through 30# sieve.
3) Granulation
 Binder preparation: Dissolve Polyvinyl Pyrollidone K-30 in purified water.
Take weighed amount of Starch and Transfer it into the above S.S. vessel and
make uniform slurry. Filter it through muslin cloth. Boil Purified Water in a
Stainless steel container.Transfer the filtered slurry of starch and PVPK-30
gradually under constant stirring to the container. Stir for enough time to get
homogenous, translucent paste. Cool the Paste to 50-60°C.
 Kneading: The binder solution prepared in above step was added to the dry mix
of step 2 while operations the RMG at a slow speed to get dough mass.
Additional water was added to achieve the desired granulation point if the dough
mass formed was not proper and the total quantity of water was noted down.
Chopper was used for a period of 1 minute if the dough mass formed contained
sufficient quantityof lumps.
 Wet screening:
The wet mass of above step was passed through 20# sieve.
 Drying: The wet granules obtained in the above step were dried in tray drier at a
temperature of about 50-55 º C (with raking after every 10 minutes). The
granules were dried till the desired LOD was obtained ie about 3% w/w. The
drying time was noted down during this step.
 Rasping: (Dry screening):
The dried granules were passed through 20 # sieve.
4) Prelubrication:
SSG and Aerosil 200 were passed through 30 # screen and were added to the
dried granules obtained in the above step and mixed for 10 minutes in blender.
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5) Lubrication:
Weighed amount of Magnesium stearate was passed through 60 # sieve and was
added to granules obtained in the above step and mixed in the blender for 5
minutes.
6) Compression:
The compression operation was carried on Rotary Tablet Compression Machine
fitted with 6. 5 mm round shaped, standard concave punch sets having plain on
both sides at average weight 90.0 mg/tab.
5.3.3) Formulation of Domperidone SR tablets:
Table 25 Formulation of Domperidone SR tablets
Sr
No
Ingredient
Batch 001
Qty
(mg/tab)
Batch 002
Qty
(mg/tab)
Batch 003
Qty
(mg/tab)
Batch 004
Qty
(mg/tab)
1 Domperidone 20.11 20.11 20.11 20.11
2
Lactose
Monohydrate
76.89 76.89 49.39 44.09
3 HPMC K4M 26 25 12 12
4 HPMC 15 cps - - 30 30
5
Polyvinyl
Pyrrolidone
(PVP K 30)
3 5 5 5
6 Isopropyl alcohol 80ml 80ml 70ml 80ml
7
Citric Acid
monohydrate
- 1.2 12 18
8
Colloidal silicon
dioxide
(Aerosil 200)
2 1 0.5 0.5
9
Magnesium
stearate
2 1 1 0.5
Total weight (mg) 130 130 130 130
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Steps involved in the formulation of Domperidone SR tablets are as follows:
1. Sifting:
Weighed quantity of Domperidone, Lactose Monohydrate and Methocel K4M
was passed through 30 # sieve.
2. Dry mixing:
The materials of step 1 were mixed together in RMG for 10 minutes at slow
speed and were again passed through 30# sieve.
3. Granulation:
 Preparation of Binder:
Weighed amount of PVP-K-30 was transfered into a S.S. vessel containing
Isopropyl alcohol and was stirred to get a clear solution.
 Kneading:
The binder solution prepared in above step was added to the dry mix of
step 2 while operation the RMG at a slow speed to get a dough mass. Additional
IPA was added to achieve the desired granulation point if the dough mass
formed was not proper and the total quantity of water was noted down.
Chopper was used for a period of 1 minute if the dough mass formed
contained sufficient quantity of lumps.
 Wet screening:
Pass the wet mass of above step through 20# Screen.
 Drying:
Dry the wet granules of above step in tray drier at temperature 40-45°C
(with raking after 10 minutes) (approx 30 minutes). Dry the granules till LOD is
NMT 3.0% w/w. Note the drying temperature and time required .
 Rasping (Dry screening):
The dried granules obtained in above step were passed through 20# sieve.
4. Prelubrication:
Aerosil 200 was passed through 30 # screen and was added to the dried
granules obtained in the above step and mixed for 10 minutes in blender.
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5. Lubrication:
Mg stearate was passed through 60 # sieve and was added to the above
step and mixed for 5 minutes in blender.
6. Compression:
Compression operation was carried on Rotary Tablet Compression
Machine fitted with 6.5 mm round shaped, standard concave punch sets (D
tooling) having plain on both sides at average weight 130.0 mg/tab.
7. Coating:
 Preparation of Coating solution:
Isopropyl alcohol was taken in a S.S container fitted with a strrier having
variable speed regulator. Slowly Instacoat universal blue (A05D00511) was
added into it stirring continously for 30 minutes.
The coating dispersion was filtered through muslin cloth into another
tank fitted with stirrer
.
 Coating procedure:
Dedusted tablets were charged in the coating pan and preheated to about
45oC.When exhaust temperature reached 30-40oC, coating dispersion was
sprayed continuously onto rolling tablet bed at a speed of 1-2 rpm. Tablets were
intermittently checked for quality of coat and weight gain.
After completion of the coating, tablets were dried in the coating pan at
inlet temperature between 30-40oC for a period of 10 minutes.
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5.3.4) Capsule Filling:
The prepared Lafutidine blend, Domperidone IR tablets and Domperidone
SR tablets were filled in the Size ‘0’ Capsule.
The capsules were filled using semi automatic capsule filling machine.
Individual Domperidone IR tablets and Domperidone SR tablets were filled into
each of the capsule manually. Weighed amount of Lafutidine blend was further
placed in the capsule.
Table 26: Ingredient weights
Sr. No. Ingredient
Qty mg /
Capsules
Category
1. Lafutidine Blend 250.000 Powder
2 Domperidone IR Tablets 90.000 Tablets
3. Domperidone SR tablets 135.000 Tablets
4. E.H.G. Capsules Size “0” 91.0 Capsule Shell
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RESULT AND DISCUSSION
1.  Preformulation Study
The preformulation study was carried out by studying various aspects of
characteristics of API as well as by compatibility study.
Preformulatin study consists of
 Pre-compresson Parameters.
 Post-compression Parameters.
This includes Loss on Drying of dried granules and final blend, bulk density, tapped
density, Carr’s Index, Hausner’s Ratio and sieve analysis in pre-compression
parameters and average weight, thickness, hardness, disintegration time, friability,
and in-vitro dissolution in post-compression parameters
Pre-Compression Parameters:
In process Parameters of Lafutidine Blend:
Table 27: Parameters of Lafutidine Blend
Assay (% Drug content)
Table 28: percentage of drug content
Batch 001 Batch 002 Batch 003
99.00 98.90 99.3
Sr
No
Parameters Batch 001 Batch 002 Batch 003
1 Bulk Density (gm/ml) 0.505 0.530 0.1513
2 Tapped Density (gm/ml) 0.69 0.78 0.699
3 Hausner ratio 1.366 1.344 1.272
4
Carr’s Compressibility
Index (%)
26.81 26.4 22.72
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In process parameters of Domperidone IR granules:
Table 29: parameters of Domperidone IR granules
Assay (% Drug content)
Table 30: percentage of drug content
Batch No
001
Batch No
002
Batch No
003
101.3 98.70 99
Sr
No
Parameters Batch 001 Batch 002 Batch 003
1 Bulk Density (gm/ml) 0.559 0.561 0.471
2 Tapped Density (gm/ml) 0.673 0.666 0.581
3 Hausner Ratio 1.204 1.187 1.23
4
Carr’s Compressibility
Index (%)
16.94 15.87 18.86
5
LOD Of granules (%
w/w)
2.08 2.27 2.07
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In Process Parameters of Domperidone SR granules
Table 31: Parameters of Domperidone SR granules
1.1. Pre-Compression Parameters
a) Loss on Drying (LOD)
Moisture content of Domperidone IR granules was kept between 2.0 to 2.05% w/w.
Moisture content of Domperidone SR granules was kept between 2.0 to 2.05% w/w.
b) Blend Flow Characteristics
The flow property of API i.e. Domperidone indicate that it posseses erratic
flow characteristics. Hence the method was choice was wet granulation method.
Flow Properties of Domperidone IR granules
 Bulk density in the range 0.49- 0.55 gm/ml.
 Tapped density in the range 0.58-0.67 gm/ml.
 Carr’s Index ranging 15.6-18%.
 Hausner’s ratio in the range 2.07-2.5 shows the good flow
characteristics.
Sr
no
Parameter Batch No001
Batch No
002
Batch No
003
Batch No
004
Tablets compressed using 6.5mm standard concave punch Plain on both sides
1 Bulk Density(gm/ml) 0.545 0.521 0.453 0.567
2 Tapped Density(gm/ml) 0.598 0.634 0.598 0.674
3 Hausner ratio 1.097 1.21 1.32 1.188
4
Carr’s
compressibility
index (%)
8.86 17.82 24.24 15.87
5 LOD (%w/w) 2.07 % 2.32% 2.17% 2.00%
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Flow Properties of Domperidone SR granules
 Bulk density in the range 0.52-0.6 gm/ml.
 Tapped density in the range 0.59-0.67 gm/ml.
 Carr’s Index ranging 8-15.
 Hausner’s ratio 1.09-1.2 in the range shows the good flow
characteristics.
 Post-Compression Parameters
In process Parameters of Domperidone SR granules
Table 32: Parameters of Domperidone SR granules
Sr no           Parameter Batch no 001 Batch no 002       Batch no 003
Tablets were compressed using 6.5 mm standard concave punch plain on both
sides
1 Avg weight (mg)(20 tablets) 90.8 90.90 90.2
2 Thickness (mm) 2.80 2.75 2.82
3 Hardness (N) 40 50 38
4 Friability (% w/w) 0.01 0.1 0.1
5 Disintegration time(minutes) 4 3 1
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In Process Parameters of Domperidone SR uncoated tablets
Table 33: Parameters of Domperidone SR uncoated tablets
Sr
No Parameters
Batch No
001
Batch No
002
Batch
No 003
Batch
No 004
Tablets were compressed using 6.5mm standard concave punch plain
on both sides.
1
Average
weight (mg)
(20 Tablets)
130.5 129.6 128 127.5
2 Hardness (N) 115 128 125 131
3 Thickness(mm) 3.60 3.30 3.48 3.53
In Process Parameters of Domperidone SR coated tablets
Table 34: Parameters of Domperidone SR coated tablets
Sr
No Parameters Batch 01 Batch 02 Batch 03 Batch 04
Tablets were compressed using 6.5mm standard concave punch plain
on both sides.
1
Avg weight
(mg)
(20 tablets)
133.5 134.2 132 133.2
2 Hardness (N) 120 132 130 135
3 Thickness(mm) 3.72 3.50 3.60 3.64
4 Assay 103.2% 100.5% 102.9% 101%
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1.2. Post Compression Parameters:
a. Weight Variation: There was no weight variation observed for
Domperidone IR as well as Domperidone SR tablets. Weight variation
observed in the final capsule was within limit.
b. Thickness Evaluation: Thickness of tablets was observed by using Vernier
Caliper. Thickness of both the tablets does not show any measurable
deviation.
c. Hardness Test: Hardness of the tablet was measured in ‘Newton’ unit in
digital hardness tester. The hardness of Domperidone IR tablets was found to
be between 45-50 Newton.
The hardness of Domperidone SR uncoated tablets was found to be
between 120-130 N and that of coated tablets was found to be between 130-
135 Newton.
d. Friability Test: The friability was carried out by using Roche Friabilator.
The percentage friability of tablet was ranging 0.01% - 0.1%; 0.010% -
0.030% for Domperidone IR and SR tablets. They are less than the standard
limit of 1% indicates that the prepared tablets are mechanically stable.
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2 .COMPATIBILITY STUDY
Drug–Excipient compatibility study of Lafutidine with Domperidone
capsule was carried out with different excipients .The study was carried out at
different conditions of temperature and humidity like 40°C/75%RH, 2–8°C, room
temperature & was observed for their physical appearance and assay after 2 week, 4
weeks and was compared with the initial value.
Compatibility studies between Lafutidine and Domperidone with excipients by
Differential scanning calorimetry (DSC).
DSC thermograms of pure drugs Lafutidine and Domperidone is shown below:
Figure 6: DSC thermograph of Lafutidine (Initial)
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Figure 7: DSC thermograph of Lafutidine API 1M (40ºC/75%RH)
Figure 8: DSC thermograph of Domperidone (Initial)
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Figure 9: DSC thermograph Of Lafutidine plus Domperidone (Initial)
Figure 10: DSC thermograph of Domperidone API 1M (40ºC/ 75 % RH)
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Figure10: DSC thermogram of Lafutidine plus Domperidone API 1M
(40ºC/ 75 % RH)
Figure 11: DSC thermogram of Lafutidine plus Domperidone Capsule
(Placebo) Initial
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Figure 12: DSC thermogram of Lafutidine plus Domperidone 1M (40ºC/75%
RH)
Figure 13: DSC thermogram of Lafutidine plus Domperidone Capsule (Initial)
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Figure 14: DSC thermogram of Lafutidine plus Domperidone Capsule
(40ºC/75% RH)
Figure 15: DSC thermogram of Lafutidine plus Domperidone Capsule 1 month
(40ºC/75%RH)
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DSC Discussion:
The results indicate that, there was no significant change in Physical
appearance, Assay, Related substance of drug and excipients mixture after 1 month
treatment of 40○C/ 75 % RH.
DSC thermogram of Lafutidine and Domperidone shows sharp endothermic
peak at 96.24C and 215.21C indicating the melting point of stable drug. However,
the DSC Thermograms of Lafutidine and Domperidone with all excipients shows
sharp endothermic peak at 94.37 C and 219.50C.
These thermograms indicate that was no significant changes in melting point,
peak shape, and area, peak location were found.
Therefore, this study revealed that there was no interaction between the drug,
polymers and other excipients.
3. In-vitro Drug Release Studies
The Domperidone IR tablets, Domperidone SR tablets and Lafutidine blend
were subjected to In-vitro dissolution studies.
The dissolution of Lafutidine blend and Domperidone IR tablet was carried
out in 0.1 N HCL for a period of not more than 45 minutes. The amount of both the
drugs dissolved in the prescribed media for prescribed time period was >90% which
falls under the In vitro dissolution criteria given for immediate release preparations.
The In-vitro dissolution of Domperidone SR tablets was carried out in 0.1N
HCL initially for a period of 2hrs followed by 6.8 phosphate buffer for 24hrs to
achieve better In vitro In vivo correlation (IVIVC). The amount of drug dissolved at
time point was observed to be within the In-House specification.
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Finished Product Analytical result of Lafutidine Blend
Table 35: Dissolution in 0.1 N HCL (% Cumulative release)
Sr.No. Time in
minutes
Batch 001 Batch 002 Batch 003
1 5 25.33 30.29 30.84
2 15 40.23 42.24 42.24
3 25 62.22 75.33 77.78
4 35 81.79 86.72 86.32
5 45 92.78 98 98.07
Figure16: In vitro Drug release Profile of Lafutidine blend
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Finished Product Analytical Results for Domperidone IR Tablets
Table 36: Dissolution in 0.1 N HCL (% Cumulative release).
Sr.No Time in minuet Batch 1 Batch 2 Batch
1 5 26.79 29.22 31.29
2 15 38.29 40.21 43.47
3 25 53.22 66.71 67.21
4 35 71.30 82.32 84.07
5 45 88.08 92.40 93.66
Figure 17: In vitro Drug release Profile of Domperidone IR tablets
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Finished Product analytical results of Domperidone SR tablets:
Table 37: Dissolution in 6.8 Phosphate Buffer: (% cumulative release)
Sr No
Time in
Hour
Batch No
001
Batch no
002
Batch no
003
Batch no
004
1 2 10.8 12.4 31.7 32.1
2 4 21.90 23.4 48.2 54.3
3 8 29.98 32.6 58.3 67.1
4 12 34.5 43 68.3 74.9
5 18 40.89 48.4 74.80 83.1
6 24 59.08 52 82.7 90
Figure 18: In vitro Drug release Profile of Domperidone SR tablets (Batch 001)
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Figure.19: In vitro Drug release Profile of Domperidone SR tablets (Batch 002)
Figure.20: In vitro Drug release Profile of Domperidone SR tablets (Batch 003)
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Figure 21: In vitro Drug release Profile of Domperidone SR tablets (Batch 004)
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4. STABILITY STUDY
The stability a study of final trial was done for 1 month by packing in alu-alu
blister in humidity chamber (40°C/75% RH) The result 1 month, 2 months and 3
month show. All parameters of formulation including physical parameters, content
uniformity or dissolution profile were within specification limit. So it indicates
optimized formulation were stable.
Lafutidine blend evaluated for stability studies at 400C / 75 % RH condition.
Figure 38: Dissolution data of percentage cumulative drug release`
Time in
min
Initial
Batch.No.3
30 days 60 days 90  days
5 30.84 30.83 30.82
30.31
15 42.24 42.23 42.22
42.22
25 77.78 77.76 77.75
77.75
35 86.32 86.32 86.32
86.31
45 98.07 98.07 98.06
98.06
Chapter 7 Result and Discussion
Dept of pharmaceutics 104 J.K.K.Nattraja College of Pharmacy
Figure 22: vitro Drug release Profile of Lafutidine
Domperidone IR Tablets
Figure 39: Dissolution in 0.1 N HCL (% Cumulative release).
Time Initial
Batch.No.3
30 days 60 days 90  days
5 31.29 31.29 31.28 31.27
15 43.47 43.47 43.45 43.44
25 67.21 67.20 67.18 67.18
35 84.07 84.06 84.04 84.04
45 93.66 93.65 93.65 93.64
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Figure 23: in vitro Drug release Profile of Domperidone IR Tablets
Domperidone SR tablets
Table 40: Dissolution in 6.8 PH Buffer (% cumulative release)
Time in Hour Initial
Batch.no.4
30 days 60 days 90  days
2 32.19 32.18 32.14 32.11
4 54.34 54.33 54.32 54.32
8 67.12 67.12 76.11 67.10
12 74.97 74.96 74.95 74.95
18 83.16 83.15 83.14 83.12
24 90.62 90.61 90.60 90.60
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Figure 24: in vitro Drug release Profile of Domperidone IR Tablets
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SUMMARY
The present research work aims at developing a novel drug delivery system
consisting of a H2 receptor blocker and a prokinetic agent.
The H2 blocker is a newly developed potent antisecretory agent Lafutidine
whereas the prokinetic agent is Domperidone.
Usually the H2 blockers are administered once a day while prokinetic
agents are prescribed thrice daily. The present formulation has been utilised to
tackle the differences in dosing frequency of these two drugs. The formulation
not only ensures patient convenience but also gives high relief rate.
The drug delivery system is a Capsule consisting of Lafutidine blend,
Domperidone Immediate release tablets and Domperidone sustain release tablets.
The Capsule dosage form is the dosage form of choice as it helps in co
administration of these two drugs in two different forms to achieve better
therapeutic regimen.
The immediate release forms of Lafutidine and Domperidone are
administered to achieve quick relief of the disease state i.e. GERD and
Dyspepsia. and the sustained release form helps in administering the drug for a
period of about 24 hours to achieve prolonged therapeutic benefit.
The formulation is tested for its stability at accelerated stability conditions
and from the results obtained from stability studies, it can be concluded that the
formulation is therapeutically as well as physically stable over a period of 3
months.
The capsule containing Lafutidine blend and Domperidone immediate
release and sustain release tablets were successfully formulated by using wet
granulation method and by using different polymers.
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Formulated tablets gave satisfactory results for various evaluation
parameters like tablet thickness, hardness, weight variation, content uniformity
and in vitro drug release.
DSC study revealed that there was no interaction between the drug,
polymers and other excipients.
The formulation is tested for its stability at accelerated stability conditions
and from the results obtained from stability studies, it can be concluded that the
formulation is therapeutically as well as physically stable over a period of 3
months.
The present formulation has been utilised to tackle the differences in
dosing frequency of these two drugs. The formulation not only ensures patient
convenience but also gives high relief rate.
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CONCLUSION
 From results it can be concluded, a multifunctional system was developed
consisting of Lafutidine 10mg and Domperidone 30 mg (10mg +20mg)
encapsulated in an capsule which can be used for the treatment of symptoms
associated with GERD as well as the disease itself.
 A combination therapy of a prokinetic agent and a gastric acid lowering
compound is rational and is more effective than mono therapy.
The system so developed will be a new advantage over the currently
available monotherapy regimens for the treatment of Gastroesophagal reflux
disease and dyspepsia.
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